

APPENDIX:

Behavioral and Clinical Characteristics of People Living with Diagnosed HIV in California 2015-2017

California Department of Public Health
Center for Infectious Diseases
Office of AIDS
Medical Monitoring Project



June 2020



List of Appendix Tables

Appendix Table 3.1. Demographics, by Cycle Year	1
Appendix Table 3.2. Characteristics, Past 12 Months, by Cycle Year	3
Appendix Table 3.3. Health Insurance Coverage, Past 12 Months, by Cycle Year	5
Appendix Table 4.1. HIV Disease Stage, CD4+ Lymphocyte Counts, and Viral Suppression, by Cycle Year	7
Appendix Table 4.2. Receipt and Quality of HIV Care, by Cycle Year	8
Appendix Table 4.3. Antiretroviral Therapy (ART) Use, by Cycle Year	10
Appendix Table 4.4. Antiretroviral Medication Adherence, by Cycle Year	13
Appendix Table 4.5a. Antiretroviral Therapy (ART) Prescription by Selected Characteristics and Cycle Year	16
Appendix Table 4.5b. Antiretroviral Therapy (ART) Dose Adherence, by Selected Characteristics and Cycle Year	17
Appendix Table 4.5c. Sustained Viral Suppression, by Selected Characteristics and Cycle Year	19
Appendix Table 4.6a. Sexually Transmitted Infections Testing, by Cycle Year	21
Appendix Table 4.6b. Sexually Transmitted Infections Testing Among Sexually Active People Living With Diagnosed HIV, by Cycle Year	21
Appendix Table 4.7. Emergency Department/Urgent Care Clinic Use and Hospital Admission, by Cycle Year	22
Appendix Table 4.8. Gynecological Care and Reproductive Health Among Women, by Cycle Year	23
Appendix Table 5.1. Depression and Anxiety, by Cycle Year	24



List of Appendix Tables

Appendix Table 5.2. Tobacco and Electronic Cigarette Use, by Cycle Year	24
Appendix Table 5.3. Alcohol Use, by Cycle Year	26
Appendix Table 5.4. Non-Injection Drug Use, by Cycle Year	27
Appendix Table 5.5. Injection Drug Use, by Cycle Year	29
Appendix Table 6.1a. Sexual Behavior Among Cisgender Men, by Cycle Year	31
Appendix Table 6.1b. Sexual Behavior Among Cisgender Women, by Cycle Year	32
Appendix Table 6.3a. Sexual Behavior During the 12 Months Before the Interview Among Men Who Had Sex With Men (MSM), by Cycle Year	33
Appendix Table 6.3b. Sexual Behavior During the 12 Months Before the Interview Among Men Who Had Sex Only With Women (MSW), by Cycle Year	35
Appendix Table 6.3c. Sexual Behavior During the 12 Months Before the Interview Among Women Who Had Sex With Men (WSM), by Cycle Year	36
Appendix Table 7.1. Intimate Partner Violence and Sexual Violence, by Cycle Year	38
Appendix Table 8.1a. Met and Unmet Need for Ancillary Services, by Cycle Year	39
Appendix Table 8.1b. Met and Unmet Need for Ancillary Services Among People Living With Diagnosed HIV With High Stigma Score, by Cycle Year	43
Appendix Table 9.1. Prevention Services Use, by Cycle Year	47
Appendix Table 10.1. High HIV Stigma by Selected Characteristics and Cycle Year	48

This page is left intentionally blank.


Appendix Table 3.1. Demographics, by Cycle Year - Medical Monitoring Project, CA, 2015-2017

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
Male	86.5% (81.2-91.9)	86.5% (81.4-91.6)	85.2% (80.6-89.9)	524	86.1% (83.2-89.0)
Female	13.5% (8.1-18.8)	13.5% (8.4-18.6)	13.2% (8.8-17.7)	98	13.4% (10.5-16.2)
Transgender ^d	0.0%	0.0%	1.5%* (0.0-3.1)	<5 obs.	0.5%* (0.0-1.1)
Sexual Orientation					
Lesbian or gay	57.3% (48.5-66.2)	57.9% (50.4-65.4)	57.4% (50.0-64.9)	357	57.6% (53.0-62.1)
Heterosexual or straight	34.4% (26.0-42.8)	23.4% (17.2-29.6)	27.1% (20.7-33.4)	180	28.2% (24.2-32.3)
Bisexual	4.3% (1.2-7.5)*	13.2% (7.9-18.5)	12.6% (7.1-18.0)	59	10.1% (7.3-12.9)
Other	3.9%* (0.1-7.8)	5.5%* (1.4-9.5)	2.9%* (0.8-5.1)	23	4.1% (2.1-6.1)
Race/Ethnicity					
American Indian/Alaska Native	0.0%	2.0% (0.0-4.5)	1.2%* (0.0-2.5)	7	1.1%* (0.1-2.0)
Asian	0.7%* (0.0-2.1)	2.2%* (0.3-4.1)	3.8%* (0.6-7.0)	13	2.3%* (0.9-3.6)
Black/African American	13.7% (8.0-19.4)	18.8% (12.7-24.9)	15.6% (10.4-20.9)	104	16.1% (12.8-19.3)
Latinx ^e	36.6% (27.6-45.7)	29.4% (22.6-36.3)	35.5% (28.6-42.4)	208	33.9% (29.5-38.3)
Native Hawaiian/Other Pacific Islander	0.1%* (0.0-0.3)	0.0%	0.4%* (0.0-1.1)	<5 obs.	0.2%* (0.0-0.4)
White	41.0% (32.2-49.8)	39.1% (32.0-46.3)	39.7% (32.1-47.3)	250	39.9% (35.4-44.5)
Multiple races	7.8% (3.3-12.3)	8.4% (3.9-13.0)	3.9%* (1.5-6.3)	42	6.6% (4.4-8.9)

**Appendix Table 3.1. Demographics, by Cycle Year - Medical Monitoring Project, CA, 2015-2017 (cont.)**

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
Age at Time of Interview (yr)					
18–24	0.6%* (0.0-1.9)	1.6%* (0.0-3.3)	2.3%* (0.0-4.8)	10	1.6%* (0.4-2.7)
25–29	3.1%* (0.0-7.0)	7.0% (3.3-10.8)	4.3%* (0.8-7.7)	29	4.8% (2.7-6.9)
30–34	7.3%* (1.9-12.6)	9.1% (4.8-13.4)	8.0% (3.9-12.0)	48	8.1% (5.5-10.7)
35–39	8.2% (3.4-12.9)	5.4% (2.3-8.6)	8.0% (3.9-12.0)	44	7.2% (4.9-9.5)
40–44	10.2%* (3.4-17.0)	14.3% (8.6-20.1)	8.5% (4.8-12.1)	63	10.9% (7.8-14.1)
45–49	12.1% (7.0-17.2)	13.8% (8.6-19.1)	11.1% (6.3-15.8)	80	12.3% (9.4-15.2)
50–54	23.6% (15.8-31.5)	18.9% (13.4-24.4)	19.2% (13.4-25.1)	127	20.5% (16.8-24.3)
55–59	12.1% (7.0-17.2)	13.4% (8.0-18.8)	17.7% (12.1-23.3)	94	14.5% (11.4-17.6)
60–64	16.3% (10.1-22.4)	8.2% (4.5-11.9)	12.5% (6.9-18.1)	78	12.3% (9.3-15.3)
≥65	6.5%* (2.5-10.5)	8.1% (4.1-12.2)	8.5% (4.5-12.5)	53	7.7% (5.4-10.0)
Education					
Less than high school	18.8% (12.0-25.6)	8.9% (4.9-12.9)	10.4% (6.3-14.4)	82	12.6% (9.7-15.5)
High school diploma or GED	19.4% (12.2-26.7)	15.4% (10.5-20.3)	26.3% (19.6-33.0)	129	20.5% (16.9-24.2)
More than high school	61.8% (53.1-70.5)	75.7% (69.7-81.7)	63.3% (56.1-70.5)	413	66.9% (62.6-71.1)
Country or Territory of Birth					
United States or U.S. territory	75.0% (67.1-83.0)	80.7% (74.8-86.7)	75.3% (69.4-81.3)	480	77.0% (73.2-80.8)
Foreign born	25.0% (17.0-32.9)	19.3% (13.3-25.2)	24.7% (18.7-30.6)	143	23.0% (19.2-26.8)


Appendix Table 3.1. Demographics, by Cycle Year - Medical Monitoring Project, CA, 2015-2017 (cont.)

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
Time Since HIV Diagnosis					
<5 years	18.0% (10.4-25.6)	20.8% (14.8-26.9)	16.6% (10.9-22.2)	106	18.4% (14.7-22.1)
5-9 years	22.2% (14.5-30.0)	17.8% (12.3-23.3)	21.1% (14.8-27.4)	124	20.4% (16.6-24.2)
≥10 years	59.8% (50.7-68.9)	61.4% (54.2-68.6)	62.3% (54.9-69.7)	395	61.2% (56.6-65.7)
TOTAL	---	---	---	626	---

Abbreviations: CI, confidence interval; GED, general educational development. Note: Estimates with a coefficient of variation ≥ 0.30 , a denominator sample size < 30 , an absolute CI width ≥ 0.30 , or an absolute CI width between 0.05 and 0.30 and a relative CI width $> 130\%$ are marked with an asterisk and should be interpreted with caution. ^a Percentages are weighted percentages. ^b CIs incorporate weighted percentages. ^c Numbers are unweighted. ^d People were classified as transgender if sex at birth and gender reported by the person were different, or if the person chose "transgender" in response to the question about self-identified gender. ^e Latinx people might be of any race. Persons are classified in only one race/ethnicity category.

Appendix Table 3.2. Characteristics, Past 12 Months, by Cycle Year - Medical Monitoring Project, CA, 2015-2017

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
Homeless at Any Time^d					
Yes	13.8% (6.6-21.0)	7.9% (4.0-11.8)	12.8% (7.1-18.4)	59	11.5% (8.2-14.8)
No	86.2% (79.0-93.4)	92.1% (88.2-96.0)	87.2% (81.6-92.9)	565	88.5% (85.2-91.8)
Incarcerated > 24 Hours					
Yes	5.4%* (1.1-9.7)	3.2%* (0.8-5.6)	3.5%* (0.1-6.9)	21	4.0% (2.1-6.0)
No	94.6% (90.3-98.9)	96.8% (94.4-99.2)	96.5% (93.1-99.9)	603	96.0% (94.0-97.9)
Any Disability^e					
Yes	35.4% (26.9-43.9)	35.9% (28.8-43.0)	43.9% (36.4-51.3)	261	38.5% (34.1-42.9)
No	64.6% (56.1-73.1)	64.1% (57.0-71.2)	56.1% (48.7-63.6)	362	61.5% (57.1-65.9)

Appendix Table 3.2. Characteristics, Past 12 Months, by Cycle Year - Medical Monitoring Project, CA, 2015-2017 (cont.)

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
Received Supplemental Security Income (SSI)					
Yes	20.5% (13.2-27.7)	14.9% (9.5-20.3)	18.2% (12.7-23.6)	113	17.8% (14.4-21.3)
No	79.5% (72.3-86.8)	85.1% (79.7-90.5)	81.8% (76.4-87.3)	507	82.2% (78.7-85.6)
Received Social Security Disability Insurance (SSDI)					
Yes	31.4% (23.3-39.5)	26.1% (19.6-32.6)	23.4% (17.1-29.6)	172	26.9% (22.9-30.9)
No	68.6% (60.5-76.7)	73.9% (67.4-80.4)	76.6% (70.4-82.9)	451	73.1% (69.1-77.1)
Went Without Food Due to Lack of Money					
Yes	22.3% (14.6-30.1)	22.7% (16.1-29.3)	20.2% (14.0-26.4)	128	21.7% (17.7-25.6)
No	77.7% (69.9-85.4)	77.3% (70.7-83.9)	79.8% (73.6-86.0)	496	78.3% (74.4-82.3)
Employment Status^f					
Employed	44.4% (35.3-53.5)	49.2% (41.7-56.7)	45.7% (38.2-53.3)	288	46.4% (41.8-51.0)
Unemployed	40.2% (31.5-48.9)	37.6% (30.4-44.8)	40.5% (33.0-47.9)	252	39.5% (35.0-43.9)
Student	3.4%* (0.6-6.2)	1.6%* (0.0-3.2)	2.4%* (0.2-4.5)	15	2.5% (1.2-3.7)
Retired	12.0% (6.3-17.6)	11.6% (6.5-16.7)	11.5% (6.6-16.3)	68	11.7% (8.7-14.7)
Combined Yearly Household Income (U.S.\$)^g					
0-19,999	46.1% (37.1-55.1)	39.5% (32.2-46.8)	40.5% (33.0-48.0)	260	42.0% (37.4-46.6)
20,000-39,999	24.4% (16.6-32.2)	25.4% (18.2-32.5)	26.3% (19.4-33.1)	147	25.4% (21.2-29.5)
40,000-74,999	17.3% (10.7-23.9)	16.9% (11.2-22.5)	18.5% (12.1-24.8)	107	17.6% (14.0-21.1)
≥75,000	12.2% (6.6-17.9)	18.3% (12.7-23.9)	14.8% (9.6-20.0)	98	15.1% (11.9-18.2)


Appendix Table 3.2. Characteristics, Past 12 Months, by Cycle Year - Medical Monitoring Project, CA, 2015-2017 (cont.)

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
Poverty Guidelines^h					
Above poverty threshold	66.7% (58.2-75.2)	77.6% (71.8-83.5)	72.6% (66.1-79.1)	437	72.3% (68.2-76.4)
At or below poverty threshold	33.3% (24.8-41.8)	22.4% (16.5-28.2)	27.4% (20.9-33.9)	175	27.7% (23.6-31.8)
TOTAL	---	---	---	626	---

Abbreviations: CI, confidence interval; U.S.\$, U.S. dollar. Note: Estimates with a coefficient of variation ≥ 0.30 , a denominator sample size < 30 , an absolute CI width ≥ 0.30 , or an absolute CI width between 0.05 and 0.30 and a relative CI width $> 130\%$ are marked with an asterisk and should be interpreted with caution. ^a Percentages are weighted percentages. ^b CIs incorporate weighted percentages. ^c Numbers are unweighted. ^d Living on the street, in a shelter, in a single-room-occupancy hotel, or in a car. ^e Includes physical, mental, and emotional disabilities. ^f Employed includes employed for wages, self-employed, or homemaker. ^g Income from all sources, before taxes, in the last calendar year. ^h Poverty guidelines as defined by Federal Health and Human Services.

Appendix Table 3.3. Health Insurance Coverage, Past 12 Months, by Cycle Year - Medical Monitoring Project, CA, 2015-2017

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
Health Insurance or Coverage for Medications^d					
Yes	98.6% (95.8-100.0)	100.0%	98.8% (96.6-100.0)	621	99.1% (97.9-100.0)
No	1.4%* (0.0-4.2)	0.0%	1.2%* (0.0-3.4)	<5 obs.	0.9%* (0.0-2.1)
Type of Health Insurance or Coverage for Medications:					
Ryan White or ADAP					
Yes	52.8% (43.7-61.8)	47.5% (40.1-55.0)	46.2% (38.6-53.7)	316	48.7% (44.1-53.4)
No	47.2% (38.2-56.3)	52.5% (45.0-59.9)	53.8% (46.3-61.4)	299	51.3% (46.6-55.9)
Medicaid					
Yes	51.5% (42.4-60.6)	57.7% (50.3-65.1)	51.3% (43.7-58.9)	343	53.5% (48.8-58.1)
No	48.5% (39.4-57.6)	42.3% (34.9-49.7)	48.7% (41.1-56.3)	279	46.5% (41.9-51.2)

**Appendix Table 3.3. Health Insurance Coverage, Past 12 Months, by Cycle Year - Medical Monitoring Project, CA, 2015-2017 (cont.)**

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
Private Health Insurance					
Yes	32.4% (24.1-40.7)	38.4% (31.2-45.5)	40.2% (32.7-47.7)	240	37.1% (32.7-41.5)
No	67.6% (59.3-75.9)	61.6% (54.5-68.8)	59.8% (52.3-67.3)	377	62.9% (58.5-67.3)
Medicare					
Yes	27.6% (20.2-35.0)	34.7% (27.4-41.9)	33.6% (26.3-41.0)	205	32.0% (27.8-36.3)
No	72.4% (65.0-79.8)	65.3% (58.1-72.6)	66.4% (59.0-73.7)	410	68.0% (63.7-72.2)
Other Public Insurance					
Yes	12.5% (5.6-19.3)	10.7% (6.3-15.2)	10.6% (5.4-15.8)	59	11.2% (8.0-14.5)
No	87.5% (80.7-94.4)	89.3% (84.8-93.7)	89.4% (84.2-94.6)	553	88.8% (85.5-92.0)
Tricare/CHAMPUS or Veterans Administration					
Yes	4.2%* (1.1-7.2)	5.7%* (1.3-10.1)	7.2%* (1.9-12.4)	26	5.7% (3.2-8.2)
No	95.8% (92.8-98.9)	94.3% (89.9-98.7)	92.8% (87.6-98.1)	589	94.3% (91.8-96.8)
Insurance Type Unknown^e					
Yes	1.2%* (0.0-2.8)	0.0%	0.4%* (0.0-1.1)	<5 obs.	0.5%* (0.0-1.1)
No	98.8% (97.2-100.0)	100.0%	99.6% (98.9-100.0)	612	99.5% (98.9-100.0)
TOTAL	---	---	---	626	---

Abbreviations: CI, confidence interval; CHAMPUS, Civilian Health and Medical Program of the Uniformed Services; ADAP, AIDS Drug Assistance Program. Note: Estimates with a coefficient of variation ≥ 0.30 , a denominator sample size < 30 , an absolute CI width ≥ 0.30 , or an absolute CI width between 0.05 and 0.30 and a relative CI width $> 130\%$ are marked with an asterisk and should be interpreted with caution. ^a Percentages are weighted percentages. ^b CIs incorporate weighted percentages. ^c Numbers are unweighted. ^d People could select more than 1 response for health insurance or coverage for medications (including antiretroviral medications). ^e Unknown insurance type means that the person had insurance or coverage for medications (including antiretroviral medications), but the type of insurance or coverage could not be determined.


Appendix Table 4.1. HIV Disease Stage, CD4+ Lymphocyte Counts, and Viral Suppression, by Cycle Year - Medical Monitoring Project, CA, 2015-2017

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
<i>HIV Infection Stage 3 (AIDS)^d</i>					
Yes	57.4% (48.6-66.2)	59.1% (51.7-66.5)	55.1% (47.5-62.7)	363	57.1% (52.6-61.7)
No	42.6% (33.8-51.4)	40.9% (33.5-48.3)	44.9% (37.3-52.5)	263	42.9% (38.3-47.4)
<i>Geometric Mean CD4 Count (cells/μL)</i>					
0-199	11.0% (4.9-17.1)	8.3% (4.2-12.3)	3.7%* (0.9-6.5)	37	7.8% (5.1-10.5)
200-349	6.7% (3.0-10.4)	9.7% (4.7-14.7)	12.9% (7.7-18.1)	54	9.6% (7.0-12.3)
350-499	18.6% (11.6-25.6)	21.6% (14.6-28.6)	18.6% (12.3-24.9)	97	19.6% (15.6-23.5)
\geq 500	63.8% (54.8-72.7)	60.4% (52.4-68.5)	64.8% (57.2-72.5)	313	63.0% (58.2-67.8)
<i>Lowest CD4 Count (cells/μL), Past 12 Months</i>					
0-49	2.4%* (0.0-5.1)	2.7%* (0.3-5.0)	3.8%* (0.5-7.2)	14	2.9% (1.3-4.5)
50-199	10.1% (4.3-15.9)	9.2% (4.3-14.0)	6.4%* (2.6-10.2)	42	8.6% (5.8-11.5)
200-349	9.3% (4.7-13.9)	12.3% (7.5-17.1)	12.5% (7.4-17.5)	66	11.3% (8.5-14.1)
350-499	19.4% (12.4-26.4)	21.8% (14.8-28.7)	17.7% (11.5-23.8)	99	19.6% (15.7-23.5)
\geq 500	58.8% (49.6-67.9)	54.1% (46.0-62.2)	59.7% (51.8-67.5)	287	57.5% (52.7-62.4)
<i>Viral Suppression</i>					
Most recent viral load documented undetectable or <200 copies/mL	75.1% (67.4-82.9)	70.9% (63.7-78.1)	68.3% (61.0-75.6)	456	71.3% (67.0-75.6)
Most recent viral load documented detectable, \geq 200 copies/mL, or missing/unknown	24.9% (17.1-32.6)	29.1% (21.9-36.3)	31.7% (24.4-39.0)	170	28.7% (24.4-33.0)

Appendix Table 4.1. HIV Disease Stage, CD4+ Lymphocyte Counts, and Viral Suppression, by Cycle Year - Medical Monitoring Project, CA, 2015-2017 (cont.)

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
Sustained Viral Suppression					
All viral load measurements documented undetectable or <200 copies/mL	68.7% (60.2-77.2)	64.5% (57.2-71.9)	64.3% (56.8-71.8)	425	65.8% (61.3-70.3)
Any viral load ≥200 copies/mL or missing/unknown	31.3% (22.8-39.8)	35.5% (28.1-42.8)	35.7% (28.2-43.2)	201	34.2% (29.7-38.7)
TOTAL	---	---	---	626	---

Abbreviations: CD4, CD4 T-lymphocyte count (cells/μL); CI, confidence interval. Source of disease stage information: CDC. Revised surveillance case definition for HIV infection—United States, 2014. MMWR 2014;63(RR-03):1–10. <https://www.cdc.gov/mmwr/indrr-2014.html>. Accessed August 21, 2019. Note: CD4 counts and viral load measurements are from medical record abstraction. Estimates with a coefficient of variation ≥0.30, a denominator sample size <30, an absolute CI width ≥0.30, or an absolute CI width between 0.05 and 0.30 and a relative CI width >130% are marked with an asterisk and should be interpreted with caution. ^a Percentages are weighted percentages. ^b CIs incorporate weighted percentages. ^c Numbers are unweighted. ^d HIV infection, stage 3 (AIDS): documentation of an AIDS-defining condition or either a CD4 count of <200 cells/μL or a CD4 percentage of total lymphocytes of <14. Documentation of an AIDS-defining condition supersedes a CD4 count or percentage that would not, by itself, be the basis for a stage 3 (AIDS) classification.

Appendix Table 4.2. Receipt and Quality of HIV Care, by Cycle Year - Medical Monitoring Project, CA, 2015-2017

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
Ever Received Outpatient HIV Care^d					
Yes	100.0%	100.0%	100.0%	626	100.0%
No	0.0%	0.0%	0.0%	0	0.0%
Received Outpatient HIV Care, Past 12 Months^d					
Yes	98.3% (95.4-100.0)	100.0%	98.9% (96.6-100.0)	623	99.0% (97.8-100.0)
No	1.7%* (0.0-4.6)	0.0%	1.1%* (0.0-3.4)	<5 obs.	1.0%* (0.0-2.2)
Received Outpatient HIV Care, Past 24 Months^d					
Yes	98.3% (95.4-100.0)	100.0%	98.9% (96.6-100.0)	623	99.0% (97.8-100.0)
No	1.7%* (0.0-4.6)	0.0%	1.1%* (0.0-3.4)	<5 obs.	1.0%* (0.0-2.2)


Appendix Table 4.2. Receipt and Quality of HIV Care, by Cycle Year - Medical Monitoring Project, CA, 2015-2017 (cont.)

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
Retained in Care, Past 12 Months^e					
Yes	86.8% (79.9-93.7)	80.8% (74.2-87.4)	84.3% (78.5-90.2)	515	84.0% (80.3-87.7)
No	13.2% (6.3-20.1)	19.2% (12.6-25.8)	15.7% (9.8-21.5)	89	16.0% (12.3-19.7)
Retained in Care, Past 24 Months^e					
Yes	65.8% (57.0-74.7)	59.0% (51.4-66.6)	63.0% (55.4-70.5)	387	62.6% (58.0-67.2)
No	34.2% (25.3-43.0)	41.0% (33.4-48.6)	37.0% (29.5-44.6)	216	37.4% (32.8-42.0)
Prescribed ART, Past 12 Months^f					
Yes	89.1% (83.5-94.6)	82.7% (76.4-89.0)	82.6% (76.2-89.1)	543	84.7% (81.1-88.3)
No	10.9% (5.4-16.5)	17.3% (11.0-23.6)	17.4% (10.9-23.8)	83	15.3% (11.7-18.9)
Prescribed PCP Prophylaxis, Past 12 Months^g					
Yes	25.0%* (2.7-47.4)	50.3%* (25.3-75.4)	18.3%* (0.0-38.1)	19	31.9% (18.3-45.4)
No	75.0%* (52.6-97.3)	49.7%* (24.6-74.7)	81.7%* (61.9-100.0)	30	68.1% (54.6-81.7)
Prescribed MAC Prophylaxis, Past 12 Months^h					
Yes	34.4%* (0.0-89.3)	0.0%	0.0%	<5 obs.	12.2%* (0.0-34.4)
No	65.6%* (10.7-100.0)	100.0%	100.0%	10	87.8%* (65.6-100.0)
Received Influenza Vaccination, Past 12 Months					
Yes	80.8% (73.5-88.1)	72.5% (65.4-79.5)	81.9% (76.1-87.7)	490	78.5% (74.6-82.3)
No	19.2% (11.9-26.5)	27.5% (20.5-34.6)	18.1% (12.3-23.9)	132	21.5% (17.7-25.4)

Appendix Table 4.2. Receipt and Quality of HIV Care, by Cycle Year - Medical Monitoring Project, CA, 2015-2017 (cont.)

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
TOTAL	---	---	---	626	---

Abbreviations: CI, confidence interval; ART, antiretroviral therapy; PCP, Pneumocystis pneumonia; MAC, Mycobacterium avium complex; CD4, CD4 T-lymphocyte count (cells/ μ L). Note: CD4 counts, viral load measurements, prophylaxes, and vaccinations are from medical record abstraction. Measurement period is the 12 months before the interview unless otherwise noted. Note: Estimates with a coefficient of variation ≥ 0.30 , a denominator sample size < 30 , an absolute CI width ≥ 0.30 , or an absolute CI width between 0.05 and 0.30 and a relative CI width $> 130\%$ are marked with an asterisk and should be interpreted with caution. ^a Percentages are weighted percentages. ^b CIs incorporate weighted percentages. ^c Numbers are unweighted. ^d Outpatient HIV care was defined as any documentation of the following: encounter with an HIV care provider, viral load test result, CD4 test result, HIV resistance test or tropism assay, ART prescription, PCP prophylaxis, or MAC prophylaxis. ^e Two elements of outpatient HIV care at least 90 days apart in each 12-month period. ^f ART prescription documented in medical record; persons with no medical record abstraction were considered to have no documentation of ART prescription. ^g Among persons with CD4 cell count < 200 cells/ μ L. ^h Among persons with CD4 cell count < 50 cells/ μ L.

Appendix Table 4.3. Antiretroviral Therapy (ART) Use, by Cycle Year - Medical Monitoring Project, CA, 2015-2017

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
Ever Taken ART					
Yes	98.3% (96.4-100.0)	97.1% (93.8-100.0)	99.3% (98.0-100.0)	616	98.3% (96.9-99.6)
No	1.7%* (0.0-3.6)	2.9%* (0.0-6.2)	0.7%* (0.0-2.0)	8	1.7%* (0.4-3.1)
Currently Taking ART					
Yes	92.2% (87.3-97.2)	94.4% (90.1-98.7)	93.9% (89.4-98.3)	595	93.5% (90.9-96.1)
No	7.8%* (2.8-12.7)	5.6%* (1.3-9.9)	6.1%* (1.7-10.6)	29	6.5% (3.9-9.1)
Reasons for Never Taking ART^d:					
Health care provider never discussed taking ART with person					
Yes	0.0%*	0.0%*	0.0%*	0	0.0%*
No	100.0%*	100.0%*	100.0%*	8	100.0%*


Appendix Table 4.3. Antiretroviral Therapy (ART) Use, by Cycle Year - Medical Monitoring Project, CA, 2015-2017 (cont.)

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
Health care provider said person should not start taking ART					
Yes	100.0%*	41.4%* (0.0-100.0)	100.0%*	6	68.1%* (29.9-100.0)
No	0.0%*	58.6%* (0.0-100.0)	0.0%*	<5 obs.	31.9%* (0.0-70.1)
Money or insurance problems					
Yes	33.8%* (0.0-87.7)	0.0%*	0.0%*	<5 obs.	10.8%* (0.0-31.5)
No	66.2%* (12.3-100.0)	100.0%*	100.0%*	7	89.2%* (68.5-100.0)
Person doesn't believe he/she needs ART					
Yes	7.5%* (0.0-24.2)	17.3%* (0.0-51.9)	100.0%*	<5 obs.	26.6%* (0.0-59.1)
No	92.5% (75.8-100.0)	82.7%* (48.1-100.0)	0.0%*	<5 obs.	73.4%* (40.9-100.0*)
Person thinks ART would make him/her feel sick or harm him/her					
Yes	41.8%* (0.0-100.0)	0.0%*	100.0%*	<5 obs.	26.1%* (0.0-59.3)
No	58.2%* (0.0-100.0)	100.0%*	0.0%*	<5 obs.	73.9%* (40.7-100.0)
Person decided not to take ART for some other reason					
Yes	6.0%* (0.0-19.1)	58.6%* (0.0-100.0)	0.0%*	<5 obs.	33.8%* (0.0-72.0)
No	94.0%* (80.9-100.0)	41.4%* (0.0-100.0)	100.0%*	<5 obs.	66.2%* (28.0-100.0*)
Reasons for Not Currently Taking ART, Among Those Persons With a History of ART Use^d:					
Health care provider never discussed restarting ART with person					
Yes	23.3%* (0.0-61.8)	44.7%* (0.0-99.8)	42.2%* (0.8-83.7)	<5 obs.	34.9%* (9.3-60.6)
No	76.7%* (38.2-100.0)	55.3%* (0.2-100.0)	57.8%* (16.3-99.2)	17	65.1%* (39.4-90.7)

**Appendix Table 4.3. Antiretroviral Therapy (ART) Use, by Cycle Year - Medical Monitoring Project, CA, 2015-2017 (cont.)**

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
Health care provider said person should not take ART					
Yes	9.5%* (0.0-28.0)	6.1%* (0.0-19.2)	0.0%	<5 obs.	5.0%* (0.0-13.0)
No	90.5%* (72.0-100.0)	93.9%* (80.8-100.0)	100.0%	19	95.0%* (87.0-100.0)
Money or insurance problems					
Yes	30.9%* (0.0-69.5)	93.9%* (80.8-100.0)	43.5%* (3.5-83.5)	10	47.7%* (22.8-72.5)
No	69.1%* (30.5-100.0)	6.1%* (0.0-19.2)	56.5%* (16.5-96.5)	11	52.3%* (27.5-77.2)
Person doesn't believe he/she needs ART					
Yes	39.0%* (0.0-78.0)	6.1%* (0.0-19.2)	77.6%* (48.4-100.0)	9	48.5%* (23.5-73.4)
No	61.0%* (22.0-100.0)	93.9%* (80.8-100.0)	22.4%* (0.0-51.6)	12	51.5%* (26.6-76.5)
Person thinks ART would make him/her feel sick or harm him/ her					
Yes	15.6%* (0.0-37.6)	0.0%*	50.1%* (9.5-90.7)	<5 obs.	26.6%* (4.4-48.8)
No	84.4%* (62.4-100.0)	100.0%*	49.9%* (9.3-90.5)	16	73.4%* (51.2-95.6)
Person decided not to take ART for some other reason					
Yes	38.3%* (2.8-73.7)	61.8%* (15.6-100.0)	42.5%* (1.0-83.9)	8	44.3%* (19.6-69.1)
No	61.7%* (26.3-97.2)	38.2%* (0.0-84.4)	57.5%* (16.1-99.0)	13	55.7%* (30.9-80.4)
TOTAL	---	---	---	626	---

Abbreviation: CI, confidence interval. ^a Percentages are weighted percentages. ^b CIs incorporate weighted percentages. ^c Numbers are unweighted. ^d People could select more than one response for reasons not taking ART.


Appendix Table 4.4. Antiretroviral Medication Adherence, by Cycle Year - Medical Monitoring Project, CA, 2015-2017

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
ART Adherence in the Past 30 Days:					
<i>How many days did you miss at least 1 dose of any of your HIV medicines?</i>					
0	60.3% (51.2-69.4)	56.9% (49.3-64.5)	63.4% (56.0-70.7)	356	60.2% (55.6-64.9)
1-2	21.8% (14.2-29.5)	29.6% (22.6-36.7)	26.9% (20.3-33.6)	154	26.2% (22.1-30.3)
3-5	12.9% (7.0-18.8)	10.6% (5.4-15.9)	5.4% (2.5-8.3)	61	9.5% (6.8-12.2)
6-10	2.5%* (0.0-6.5)	2.7%* (0.7-4.8)	3.8%* (0.2-7.4)	18	3.1%* (1.2-5.0)
11+	2.5%* (0.0-4.9)	0.1%* (0.0-0.4)	0.5%* (0.0-1.4)	6	1.0%* (0.2-1.8)
<i>How well did you do at taking your HIV medicines in the way you were supposed to?</i>					
Very poor	0.5%* (0.0-1.5)	0.4%* (0.0-1.3)	1.3%* (0.0-2.7)	6	0.8%* (0.1-1.4)
Poor	3.1%* (0.0-6.7)	2.2%* (0.0-4.9)	0.8%* (0.0-1.9)	11	2.0%* (0.5-3.5)
Fair	9.3%* (2.8-15.9)	6.5%* (2.6-10.4)	5.6%* (1.6-9.6)	35	7.1%* (4.3-9.9)
Good	4.7%* (1.6-7.7)	17.7% (11.8-23.6)	14.1% (9.0-19.2)	82	12.3% (9.4-15.1)
Very good	27.6% (19.6-35.7)	23.9% (17.4-30.5)	22.6% (16.9-28.4)	152	24.6% (20.7-28.5)
Excellent	54.8% (45.4-64.1)	49.3% (41.7-56.8)	55.6% (48.1-63.1)	309	53.2% (48.5-57.9)
<i>How often did you take your HIV medicines in the way you were supposed to?</i>					
Never	0.5%* (0.0-1.5)	1.8%* (0.0-4.6)	0.0%	<5 obs.	0.8%* (0.0-1.7)
Rarely	0.7%* (0.0-1.9)	0.4%* (0.0-1.3)	0.9%* (0.0-2.1)	<5 obs.	0.7%* (0.0-1.3)
Sometimes	1.3%* (0.0-2.9)	1.2%* (0.0-2.5)	3.7%* (0.2-7.3)	14	2.1%* (0.7-3.5)
Usually	4.0%* (0.9-7.2)	5.6%* (2.0-9.2)	3.7%* (1.2-6.1)	29	4.4% (2.7-6.2)

**Appendix Table 4.4. Antiretroviral Medication Adherence, by Cycle Year - Medical Monitoring Project, CA, 2015-2017 (cont.)**

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
<i>How often did you take your HIV medicines in the way you were supposed to? (cont.)</i>					
Almost always	26.4% (17.9-34.8)	30.0% (22.9-37.1)	26.0% (19.7-32.4)	168	27.4% (23.2-31.6)
Always	67.2% (58.4-76.0)	61.0% (53.5-68.5)	65.7% (58.6-72.7)	377	64.6% (60.1-69.1)
<i>How often were you troubled by ART side effects?</i>					
Never	64.7% (55.9-73.4)	60.0% (52.6-67.5)	68.1% (61.0-75.3)	375	64.4% (59.9-68.8)
Rarely	16.9% (10.5-23.4)	22.6% (16.2-29.1)	17.7% (12.0-23.4)	118	19.1% (15.5-22.6)
About half the time	10.0% (4.3-15.6)	5.7%* (2.1-9.3)	5.5% (2.4-8.6)	43	7.0% (4.6-9.4)
Most of the time	3.1%* (0.3-5.9)	6.8% (2.8-10.7)	6.0%* (1.7-10.3)	28	5.3% (3.1-7.5)
Always	5.3%* (0.9-9.8)	4.8%* (1.8-7.9)	2.7%* (0.7-4.7)	24	4.2% (2.4-6.1)
<i>Reasons for Last Missed ART Dose^d:</i>					
<i>Had a problem getting a prescription, a refill, insurance coverage, or paying for HIV medicines</i>					
Yes	17.3% (10.4-24.2)	21.1% (14.9-27.4)	23.0% (16.1-29.9)	119	20.6% (16.7-24.4)
No	82.7% (75.8-89.6)	78.9% (72.6-85.1)	77.0% (70.1-83.9)	473	79.4% (75.6-88.3)
<i>In the hospital or too sick to take HIV medicines</i>					
Yes	9.8%* (3.5-16.2)	6.8% (3.3-10.2)	7.3% (4.0-10.5)	52	7.9% (5.3-10.5)
No	90.2% (83.8-96.5)	93.2% (89.8-96.7)	92.7% (89.5-96.0)	540	92.1% (89.5-94.7)
<i>Fell asleep early or overslept</i>					
Yes	35.0% (25.8-44.2)	32.3% (25.1-39.6)	35.8% (28.6-43.0)	203	34.4% (29.9-38.9)
No	65.0% (55.8-74.2)	67.7% (60.4-74.9)	64.2% (57.0-71.4)	389	65.6% (61.1-70.1)


Appendix Table 4.4. Antiretroviral Medication Adherence, by Cycle Year - Medical Monitoring Project, CA, 2015-2017 (cont.)

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
<i>Change in your daily routine or were out of town</i>					
Yes	34.4% (25.9-43.0)	31.6% (24.7-38.4)	37.9% (30.5-45.3)	212	34.7% (30.3-39.1)
No	65.6% (57.0-74.1)	68.4% (61.6-75.3)	62.1% (54.7-69.5)	378	65.3% (60.9-69.7)
<i>Had side effects from your HIV medicines</i>					
Yes	5.3%* (1.7-8.9)	11.0% (5.7-16.2)	9.2% (5.5-12.9)	55	8.6% (6.1-11.0)
No	94.7% (91.1-98.3)	89.0% (83.8-94.3)	90.8% (87.1-94.5)	537	91.4% (89.0-93.9)
<i>Felt depressed or overwhelmed</i>					
Yes	18.1% (10.8-25.5)	14.7% (9.5-20.0)	13.7% (9.0-18.4)	98	15.4% (12.1-18.8)
No	81.9% (74.5-89.2)	85.3% (80.0-90.5)	86.3% (81.6-91.0)	494	84.6% (81.2-87.9)
<i>Was drinking or using drugs</i>					
Yes	5.3%* (0.7-9.9)	9.7% (5.6-13.9)	7.2% (3.0-11.4)	46	7.4% (5.0-9.9)
No	94.7% (90.1-99.3)	90.3% (86.1-94.4)	92.8% (88.6-97.0)	546	92.6% (90.1-95.0)
<i>Forgot to take HIV medicines</i>					
Yes	55.7% (46.3-65.1)	63.1% (56.0-70.3)	50.3% (42.6-58.0)	328	56.3% (51.6-60.9)
No	44.3% (34.9-53.7)	36.9% (29.7-44.0)	49.7% (42.0-57.4)	264	43.7% (39.1-48.4)
<i>Did not feel like taking HIV medicines</i>					
Yes	9.8% (4.5-15.0)	16.7% (10.5-22.9)	13.4% (8.1-18.6)	82	13.3% (10.1-16.5)
No	90.2% (85.0-95.5)	83.3% (77.1-89.5)	86.6% (81.4-91.9)	510	86.7% (83.5-89.9)
TOTAL	---	---	---	595	---

Abbreviation: CI, confidence interval. ^a Percentages are weighted percentages. ^b CIs incorporate weighted percentages. ^c Numbers are unweighted. ^d People could report more than one reason for last missed ART dose.

**Appendix Table 4.5a. Antiretroviral Therapy (ART) Prescription by Selected Characteristics and Cycle Year - Medical Monitoring Project, CA, 2015-2017**

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
Gender					
Male	89.0% (83.0-95.0)	82.0% (75.0-89.0)	82.4% (75.2-89.5)	453	84.4% (80.5-88.3)
Female	89.7% (74.4-100.0)	87.0% (74.7-99.2)	82.5%* (65.8-99.2)	86	86.3% (77.6-94.9)
Transgender ^d	---	---	100.0%*	<5 obs.	100.0%
Sexual Orientation					
Lesbian or gay	89.3% (82.4-96.2)	82.7% (74.2-91.2)	84.3% (75.7-93.0)	312	85.4% (80.7-90.1)
Heterosexual or straight	89.4% (78.8-99.9)	81.5% (68.9-94.0)	79.5% (66.9-92.0)	155	83.9% (77.1-90.7)
Bisexual	71.8% (37.7-100.0)	78.0%* (59.0-97.0)	81.9%* (62.2-100.0)	49	78.9% (66.2-91.5)
Other	100%*	97.7%* (92.9-100.0)	69.7%* (35.1-100.0)	20	91.4% (80.7-100.0)
Race/Ethnicity					
American Indian/Alaska Native	---	33.5%* (0.0-94.2)	68.4%* (16.2-100.0)	<5 obs.	50.0%
Asian	100.0%	80.1%* (44.9-100.0)	47.5%* (4.6-90.4)	9	62.9%* (31.3-94.4)
Black/African American	94.5% (83.9-100.0)	73.9%* (55.6-92.3)	82.9%* (64.2-100.0)	92	82.6% (72.4-92.9)
Latinx ^e	88.4% (79.1-97.7)	80.9% (68.9-93.0)	80.2% (69.6-90.8)	179	83.2% (77.0-89.4)
Native Hawaiian/Other Pacific Islander	100.0%*	---	100.0%*	<5 obs.	100.0%*
White	85.6% (75.6-95.6)	90.2% (83.6-96.8)	87.0% (69.6-90.8)	219	87.6% (82.5-92.6)
Multiple races	100.0%*	84.6%* (67.6-100.0)	100.0%*	38	92.9% (85.6-100.0)


Appendix Table 4.5a. Antiretroviral Therapy (ART) Prescription by Selected Characteristics and Cycle Year - Medical Monitoring Project, CA, 2015-2017 (cont.)

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
Age at Time of Interview (yr)					
18-29	84.6% (54.1-100.0)	75.8%* (50.8-100.0)	94.1% (82.4-100.0)	34	84.2% (70.1-98.2)
30-39	91.1% (80.3-100.0)	70.3%* (50.2-90.4)	77.5%* (58.3-96.6)	77	79.7% (69.1-90.2)
40-49	91.0% (81.1-100.0)	79.4% (65.5-93.3)	81.1% (66.3-95.9)	125	83.5% (75.7-91.3)
≥50	88.1% (80.1-96.1)	89.5% (83.8-95.2)	83.3% (75.0-91.5)	307	86.7% (82.3-91.1)
TOTAL	---	---	---	543	---

Abbreviations: CI, confidence interval. ^a Percentages are weighted percentages. ^b CIs incorporate weighted percentages. ^c Numbers are unweighted. ^d People were classified as transgender if sex at birth and gender reported by the person were different, or if the person chose "transgender" in response to the question about self-identified gender. ^e Latinx people might be of any race. Persons are classified in only one race/ethnicity category.

Appendix Table 4.5b. Antiretroviral Therapy (ART) Dose Adherence^a by Selected Characteristics and Cycle Year - Medical Monitoring Project, CA, 2015-2017

	2015	2016	2017		TOTAL
	% ^b (95% CI) ^c	% ^b (95% CI) ^c	% ^b (95% CI) ^c	# ^d	% ^b (95% CI) ^c
Gender					
Male	60.3% (50.2-70.3)	55.7% (47.5-63.9)	63.7% (55.6-71.8)	297	60.0%
Female	60.4% (39.7-81.2)	64.0%* (45.4-82.5)	63.4%* (47.4-79.5)	57	62.6% (51.8-73.4)
Transgender ^e	---	---	45.3%* (0.0-94.8)	<5 obs.	45.3%* (0.0-94.6)
Sexual Orientation					
Lesbian or gay	60.1% (47.3-72.6)	56.0% (46.1-65.9)	65.9% (56.3-75.5)	210	60.8% (54.7-67.0)
Heterosexual or straight	66.0% (52.2-79.8)	62.1% (47.9-76.4)	65.6% (53.6-77.5)	106	64.8% (57.0-72.6)
Bisexual	36.5%* (0.0-77.4)	52.6%* (30.3-74.9)	48.3%* (23.2-73.4)	27	48.8%* (33.3-64.4)
Other	29.7%* (0.0-69.9)	57.5%* (19.3-95.6)	39.4%* (3.8-75.0)	10	44.3%* (20.0-68.6)

Appendix Table 4.5b. Antiretroviral Therapy (ART) Dose Adherence^a by Selected Characteristics and Cycle Year - Medical Monitoring Project, CA, 2015-2017 (cont.)

	2015	2016	2017		TOTAL
	% ^b (95% CI) ^c	% ^b (95% CI) ^c	% ^b (95% CI) ^c	# ^d	% ^b (95% CI) ^c
Race/Ethnicity					
American Indian/Alaska Native	---	59.8%* (0.0-100.0)	36.9%* (0.0-93.2)	<5 obs.	46.0%* (2.8-89.2)
Asian	100.0%	59.7%* (16.3-100.0)	100.0%	10	85.7%* (66.6-100.0)
Black/African American	60.7%* (38.3-83.1)	49.8%* (31.4-68.2)	58.5%* (40.9-76.0)	57	55.8% (44.6-67.0)
Latinx ^f	53.9%* (37.2-70.5)	57.1% (43.4-70.8)	63.6% (52.8-74.3)	112	58.2% (50.1-66.2)
Native Hawaiian/Other Pacific Islander	100.0%*	---	100.0%*	<5 obs.	100.0%*
White	63.3% (49.4-77.1)	58.3% (46.8-69.8)	65.0% (52.1-77.8)	148	62.3% (54.9-69.6)
Multiple races	70.5%* (45.2-95.9)	64.4%* (34.7-94.1)	40.0%* (10.0-70.0)	24	61.5%* (44.5-78.6)
Age at Time of Interview (yr)					
18-29	76.2%* (34.8-100.0)	65.2%* (40.6-89.9)	72.3%* (47.5-97.0)	21	70.2%* (53.5-86.9)
30-39	54.4%* (29.8-78.9)	54.3%* (35.1-73.4)	56.4%* (37.9-74.8)	46	55.0% (42.9-67.1)
40-49	57.3%* (36.2-78.4)	57.8%* (42.2-73.5)	66.0% (51.5-80.5)	84	60.0% (50.0-70.1)
≥50	62.2% (51.1-73.3)	55.9% (45.5-66.2)	63.1% (53.2-73.0)	205	60.7% (54.6-66.7)
TOTAL	---	---	---	356	---

Abbreviations: CI, confidence interval. ^a In past 30 days, 100% adherence to ART doses. ^b Percentages are weighted percentages. ^c CIs incorporate weighted percentages. ^d Numbers are unweighted. ^e People were classified as transgender if sex at birth and gender reported by the person were different, or if the person chose "transgender" in response to the question about self-identified gender. ^f Latinx people might be of any race. Persons are classified in only one race/ethnicity category.


Appendix Table 4.5c. Sustained Viral Suppression^a by Selected Characteristics and Cycle Year - Medical Monitoring Project, CA, 2015-2017

	2015	2016	2017		TOTAL
	% ^b (95% CI) ^c	% ^b (95% CI) ^c	% ^b (95% CI) ^c	# ^d	% ^b (95% CI) ^c
Gender					
Male	68.2% (58.9-77.5)	62.4% (54.3-70.4)	64.2% (55.9-72.4)	350	64.9% (60.0-69.8)
Female	71.7%* (51.4-91.9)	78.3%* (62.3-94.2)	65.2%* (46.9-83.4)	72	71.6% (60.9-82.3)
Transgender ^e	---	---	67.0%* (16.5-100.0)	<5 obs.	67.0%* (16.7-100.0)
Sexual Orientation					
Lesbian or gay	73.5% (62.7-84.2)	63.7% (54.1-73.4)	69.0% (59.2-78.9)	248	68.7% (62.9-74.5)
Heterosexual or straight	62.4% (47.6-77.1)	71.6% (58.2-85.0)	57.6% (44.2-71.0)	119	63.3% (55.0-71.5)
Bisexual	71.8%* (37.7-100.0)	54.3%* (32.3-76.2)	60.7%* (36.3-85.0)	39	59.5% (44.5-74.4)
Other	47.6%* (0.0-96.9)	65.2%* (30.4-100.0)	67.2%* (31.0-100.0)	15	60.3%* (35.5-85.0)
Race/Ethnicity					
American Indian/Alaska Native	---	38.5%* (0.0-94.2)	31.6%* (0.0-83.8)	<5 obs.	35.8%* (0.0-74.7)
Asian	100.0%*	59.7%* (16.3-100.0)	27.7%* (0.0-59.8)	7	44.9%* (15.3-74.4)
Black/African American	64.9%* (43.0-86.8)	54.9%* (36.8-72.9)	71.4%* (54.3-88.5)	68	63.3% (52.5-74.1)
Latinx ^f	68.5% (54.2-82.8)	65.5% (52.2-78.7)	61.9% (50.2-73.6)	137	65.2% (57.6-72.8)
Native Hawaiian/Other Pacific Islander	100.0%*	---	100.0%*	<5 obs.	100.0%
White	65.6% (51.8-79.4)	74.3% (64.0-84.6)	65.3% (52.5-78.1)	178	68.3% (61.1-75.5)
Multiple races	89.2% (74.2-100.0)	44.7%* (16.9-72.5)	90.8% (77.7-100.0)	30	71.1%* (54.5-87.6)

Appendix Table 4.5c. Sustained Viral Suppression^a by Selected Characteristics and Cycle Year - Medical Monitoring Project, CA, 2015-2017 (cont.)

	2015	2016	2017		TOTAL
	% ^b (95% CI) ^c	% ^b (95% CI) ^c	% ^b (95% CI) ^c	# ^d	% ^b (95% CI) ^c
Age at Time of Interview (yr)					
18–29	81.1%* (48.9-100.0)	43.1%* (19.4-66.7)	58.0%* (25.7-90.2)	21	55.7%* (36.9-74.5)
30–39	55.0%* (30.6-79.4)	61.3%* (42.6-79.9)	64.7%* (45.6-83.8)	58	60.5% (48.5-72.5)
40–49	63.9%* (44.8-83.1)	69.8%* (54.7-84.9)	66.8% (50.8-82.8)	102	67.1% (57.5-76.7)
≥50	73.3% (63.1-83.5)	66.2% (56.3-76.2)	64.1% (54.3-74.0)	244	67.9% (62.0-73.7)
TOTAL	---	---	---	425	---

Abbreviations: CI, confidence interval. ^a In past 30 days, 100% adherence to ART doses. ^b Percentages are weighted percentages. ^c CIs incorporate weighted percentages. ^d Numbers are unweighted. ^e People were classified as transgender if sex at birth and gender reported by the person were different, or if the person chose “transgender” in response to the question about self-identified gender. ^f Latinx people might be of any race. Persons are classified in only one race/ethnicity category.

Appendix Table 4.6a. Sexually Transmitted Infections Testing by Selected Characteristics and Cycle Year - Medical Monitoring Project, CA, 2015-2017

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
Gonorrhea^d					
Yes, received test	41.5% (32.4-50.6)	34.3% (27.3-41.4)	37.0% (29.5-44.4)	223	37.6% (33.0-42.2)
No test documented	58.5% (49.4-67.6)	65.7% (58.6-72.7)	63.0% (55.6-70.5)	363	62.4% (57.8-67.0)
Chlamydia^e					
Yes, received test	42.4% (33.4-51.5)	36.5% (29.2-43.7)	36.9% (29.4-44.3)	227	38.6% (34.0-43.2)
No test documented	57.6% (48.5-66.6)	63.5% (56.3-70.8)	63.1% (55.7-70.6)	359	61.4% (56.8-66.0)
Syphilis^f					
Yes, received test	59.2% (50.0-68.3)	51.6% (43.9-59.4)	57.0% (49.3-64.7)	337	56.0% (51.2-60.7)
No test documented	40.8% (31.7-50.0)	48.4% (40.6-56.1)	43.0% (35.3-50.7)	249	44.0% (39.3-48.8)


Appendix Table 4.6a. Sexually Transmitted Infections Testing by Selected Characteristics and Cycle Year - Medical Monitoring Project, CA, 2015-2017 (cont.)

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
<i>Gonorrhea, Chlamydia, and Syphilis</i>					
Yes, received all 3 tests	38.0% (29.0-46.9)	31.0% (24.2-37.7)	32.7% (25.6-39.8)	203	33.9% (29.5-38.3)
Fewer than 3 tests documented	62.0% (53.1-71.0)	69.0% (62.3-75.8)	67.3% (60.2-74.4)	383	66.1% (61.7-70.5)
TOTAL	---	---	---	626	---

Abbreviations: CI, confidence interval; DFA, direct fluorescent antibody; EIA, enzyme immunoassay; ELISA, enzyme-linked immunoassay; FTA-ABS, fluorescent treponemal antibody absorbed; MHA-TP, microhemagglutination assay for antibody to *Treponema pallidum*; NAAT, nucleic acid amplification test; RPR, rapid plasma reagin; TP-PA, *T. pallidum* particle agglutination; TPHA, *T. pallidum* hemagglutination assay; VDRL, Venereal Disease Research Laboratory. Note: Information on laboratory testing for sexually transmitted diseases was based on medical record abstraction. ^a Percentages are weighted percentages. ^b CIs incorporate weighted percentages. ^c Numbers are unweighted. ^d Testing for *Neisseria gonorrhoeae* was defined as documentation of a result from culture, gram stain, EIA, NAAT, or nucleic acid probe. ^e *Chlamydia trachomatis* testing was defined as a result from culture, DFA, EIA or ELISA, NAAT, or nucleic acid probe. ^f Syphilis testing was defined as a result from nontreponemal syphilis tests (RPR or VDRL), treponemal syphilis tests (TPHA, TP-PA, MHA-TP, or FTA-ABS tests), or dark-field microscopy.

Appendix Table 4.6b. Sexually Transmitted Infections Testing Among Sexually Active^a People Living With Diagnosed HIV, by Cycle Year - Medical Monitoring Project, CA, 2015-2017

	2015	2016	2017		TOTAL
	% ^b (95% CI) ^c	% ^b (95% CI) ^c	% ^b (95% CI) ^c	# ^d	% ^b (95% CI) ^c
<i>Gonorrhea^e</i>					
Yes, received test	46.2% (34.1-58.3)	35.9% (26.5-45.3)	43.8% (33.6-54.0)	151	42.2% (36.0-48.4)
No test documented	53.8% (41.7-65.9)	64.1% (54.7-73.5)	56.2% (46.0-66.4)	195	57.8% (51.6-64.0)
<i>Chlamydia^f</i>					
Yes, received test	47.7% (35.6-59.8)	39.6% (29.7-49.4)	43.7% (33.5-53.8)	155	43.8% (37.5-50.0)
No test documented	52.3% (40.2-64.4)	60.4% (50.6-70.3)	56.3% (46.2-66.5)	191	56.2% (50.0-62.5)
<i>Syphilis^g</i>					
Yes, received test	62.9% (50.8-75.1)	49.2% (38.9-59.5)	64.2% (54.2-74.1)	212	59.0% (52.7-65.3)
No test documented	37.1% (24.9-49.2)	50.8% (40.5-61.1)	35.8% (25.9-45.8)	134	41.0% (34.7-47.3)

Appendix Table 4.6b. Sexually Transmitted Infections Testing Among Sexually Active^a People Living With Diagnosed HIV, by Cycle Year - Medical Monitoring Project, CA, 2015-2017 (cont.)

	2015	2016	2017		TOTAL
	% ^b (95% CI) ^c	% ^b (95% CI) ^c	% ^b (95% CI) ^c	# ^d	% ^b (95% CI) ^c
<i>Gonorrhea, Chlamydia, and Syphilis</i>					
Yes, received all 3 tests	42.2% (30.2-54.2)	30.2% (21.5-38.9)	37.5% (27.8-47.3)	134	36.8% (30.8-42.8)
Fewer than 3 tests documented	57.8% (45.8-69.8)	39.8% (61.1-78.5)	62.5% (52.7-72.2)	212	63.2% (57.2-69.2)
TOTAL	---	---	---	626	---

Abbreviations: CI, confidence interval; DFA, direct fluorescent antibody; EIA, enzyme immunoassay; ELISA, enzyme-linked immunoassay; FTA-ABS, fluorescent treponemal antibody absorbed; MHA-TP, microhemagglutination assay for antibody to *Treponema pallidum*; NAAT, nucleic acid amplification test; RPR, rapid plasma reagin; TP-PA, *T. pallidum* particle agglutination; TPHA, *T. pallidum* hemagglutination assay; VDRL, Venereal Disease Research Laboratory. Note: Information on laboratory testing for sexually transmitted diseases was based on medical record abstraction. ^a Sexual activity was reported in the interview component of the Medical Monitoring Project and was defined as anal or vaginal intercourse. ^b Percentages are weighted percentages. ^c CIs incorporate weighted percentages. ^d Numbers are unweighted. ^e Testing for *Neisseria gonorrhoeae* was defined as documentation of a result from culture, gram stain, EIA, NAAT, or nucleic acid probe. ^f *Chlamydia trachomatis* testing was defined as a result from culture, DFA, EIA or ELISA, NAAT, or nucleic acid probe. ^g Syphilis testing was defined as a result from nontreponemal syphilis tests (RPR or VDRL), treponemal syphilis tests (TPHA, TP-PA, MHA-TP, or FTA-ABS tests), or dark-field microscopy.

Appendix Table 4.7. Emergency Department/Urgent Care Clinic Use and Hospital Admission, by Cycle Year - Medical Monitoring Project, CA, 2015-2017

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
<i>Number of Visits to Emergency Department</i>					
0 visits	68.8% (60.8-76.7)	65.1% (58.0-72.3)	60.6% (53.1-68.1)	401	64.7% (60.3-69.1)
1 visit	17.3% (11.2-23.5)	21.9% (15.5-28.4)	22.4% (16.1-28.6)	128	20.6% (17.0-24.2)
2-4 visits	10.7% (5.2-16.2)	9.5% (5.6-13.5)	14.4% (8.7-20.2)	75	11.6% (8.7-14.6)
≥5 visits	3.2%* (0.4-6.0)	3.4%* (1.2-5.6)	2.6%* (0.0-5.3)	20	3.1% (1.6-4.5)


Appendix Table 4.7. Emergency Department/Urgent Care Clinic Use and Hospital Admission, by Cycle Year - Medical Monitoring Project, CA, 2015-2017 (cont.)

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
Number of Hospital Admissions					
0 admissions	84.6% (78.1-91.1)	86.6% (81.9-91.4)	80.6% (74.6-86.6)	521	83.9% (80.5-87.2)
1 admission	8.4% (3.9-12.9)	8.9% (4.9-13.0)	11.4% (7.0-15.9)	66	9.6% (7.1-12.1)
2-4 admissions	5.2% (0.7-9.8)*	3.7% (1.3-6.1)*	6.1% (2.3-9.9)*	31	5.0% (2.9-7.2)
≥5 admissions	1.8%* (0.0-4.3)	0.7%* (0.0-1.7)	1.9%* (0.0-4.6)	6	1.5%* (0.2-2.7)
TOTAL	---	---	---	626	---

Abbreviation: CI, confidence interval. Note: Estimates with a coefficient of variation ≥ 0.30 , a denominator sample size < 30 , an absolute CI width ≥ 0.30 , or an absolute CI width between 0.05 and 0.30 and a relative CI width $> 130\%$ are marked with an asterisk and should be interpreted with caution. ^a Percentages are weighted percentages. ^b CIs incorporate weighted percentages. ^c Numbers are unweighted.

Appendix Table 4.8. Gynecological Care and Reproductive Health Among Women, by Cycle Year - Medical Monitoring Project, CA, 2015-2017

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
Papanicolaou (Pap) Test, Past 12 Months					
Yes	78.3%* (60.5-96.0)	70.2%* (50.6-89.8)	72.3% (57.3-87.3)	72	73.6% (63.5-83.7)
No	21.7%* (4.0-39.5)	29.8%* (10.2-49.4)	27.7% (12.7-42.7)	24	26.4% (16.3-36.5)
Pregnant Since HIV Diagnosis					
Yes	20.2%* (2.6-37.9)	47.0%* (26.7-67.4)	31.4%* (16.4-46.4)	34	33.0% (22.6-43.4)
No	79.8%* (62.1-97.4)	53.0%* (32.6-73.3)	68.6%* (53.6-83.6)	63	67.0% (56.6-77.4)
TOTAL	---	---	---	98	---

Abbreviation: CI, confidence interval. Note: Measures are self-reported. ^a Percentages are weighted percentages. ^b CIs incorporate weighted percentages. ^c Numbers are unweighted.

**Appendix Table 5.1. Depression and Anxiety, by Cycle Year - Medical Monitoring Project, CA, 2015-2017**

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
Moderate or Severe Depression (PHQ-8 score ≥10)					
Yes	19.0% (12.4-25.7)	20.2% (14.0-26.4)	14.7% (9.8-19.6)	115	17.9% (14.5-21.3)
No	81.0% (74.3-87.6)	79.8% (73.6-86.0)	85.3% (80.4-90.2)	503	82.1% (78.7-85.5)
Anxiety^d					
No anxiety	78.9% (71.6-86.2)	71.6% (64.6-78.6)	80.1% (74.5-85.7)	473	77.0% (73.1-80.8)
Mild anxiety	7.8%* (2.5-13.2)	11.1% (6.0-16.3)	6.2% (2.6-9.9)	45	8.3% (5.6-11.1)
Moderate anxiety	8.3% (3.5-13.1)	8.9% (4.7-13.1)	8.4% (4.7-12.1)	57	8.5% (6.1-11.0)
Severe anxiety	4.9%* (1.7-8.1)	8.4% (4.0-12.8)	5.3% (2.5-8.0)	44	6.2% (4.1-8.2)
TOTAL	---	---	---	626	---

Abbreviations: CI, confidence interval; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, 4th edition; GAD-7, Generalized Anxiety Disorder 7-item Scale; PHQ-8, Patient Health Questionnaire. ^a Percentages are weighted percentages. ^b CIs incorporate weighted percentages. ^c Numbers are unweighted. ^d Responses to the GAD-7 were used to define "mild anxiety," "moderate anxiety" and "severe anxiety," according to criteria from the DSM-IV. "Severe anxiety" was defined as having a score of ≥15; "moderate anxiety" was defined as having a score of 10–14; and "mild anxiety" was defined as having a score of 5–9.

Appendix Table 5.2. Tobacco and Electronic Cigarette Use, by Cycle Year - Medical Monitoring Project, CA, 2015-2017

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
Smoked ≥100 Cigarettes (lifetime)					
Yes	57.5% (48.4-66.5)	57.9% (50.5-65.2)	60.0% (52.7-67.4)	361	58.5% (53.9-63.0)
No	42.5% (33.5-51.6)	42.1% (34.8-49.5)	40.0% (32.6-47.3)	262	41.5% (37.0-46.1)


Appendix Table 5.2. Tobacco and Electronic Cigarette Use, by Cycle Year - Medical Monitoring Project, CA, 2015-2017 (cont.)

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
Cigarette Smoking Status					
Current smoker	28.8% (20.6-36.9)	26.8% (20.2-33.3)	27.2% (20.3-34.1)	169	27.6% (23.4-31.7)
Former smoker	28.7% (20.8-36.6)	31.1% (24.0-38.2)	32.8% (25.7-39.9)	192	30.9% (26.7-35.2)
Never smoked	42.5% (33.5-51.6)	42.1% (34.8-49.5)	40.0% (32.6-47.3)	262	41.5% (37.0-46.1)
Frequency of Current Cigarette Smoking					
Less than monthly	4.7%* (0.0-9.4)	2.0%* (0.3-3.6)	1.6%* (0.0-3.1)	15	2.7%* (1.0-4.4)
Monthly	0.7%* (0.0-2.1)	0.3%* (0.0-0.9)	2.3%* (0.0-4.6)	6	1.1%* (0.2-2.1)
Weekly	5.1%* (1.1-9.1)	3.4%* (1.0-5.7)	6.4% (2.9-9.9)	30	5.0% (3.1-6.9)
Daily	18.2% (11.6-24.8)	21.1% (14.9-27.3)	17.0% (10.9-23.1)	118	18.7% (15.1-22.3)
Never	71.2% (63.1-79.4)	73.2% (66.7-79.8)	72.8% (65.9-79.7)	454	72.4% (68.3-76.6)
Smoked ≥50 Cigars, Cigarillos, or Little Filtered Cigars (lifetime)					
Yes	8.7% (4.3-13.1)	10.7% (6.1-15.4)	14.0% (9.2-18.9)	76	11.2% (8.6-13.9)
No	91.3% (86.9-95.7)	89.3% (84.6-93.9)	86.0% (81.1-90.8)	547	88.8% (86.1-91.4)
Cigars, Cigarillos, or Little Filtered Cigars Smoking Status					
Current smoker	4.3%* (1.0-7.6)	4.2%* (1.6-6.7)	6.1% (3.1-9.1)	35	4.9% (3.2-6.6)
Former smoker	4.4%* (1.5-7.4)	6.6%* (2.5-10.7)	8.0% (4.0-11.9)	41	6.4% (4.2-8.5)
Never smoked	91.3% (86.9-95.7)	89.3% (84.6-93.9)	86.0% (81.1-90.8)	547	88.8% (86.1-91.4)

**Appendix Table 5.2. Tobacco and Electronic Cigarette Use, by Cycle Year - Medical Monitoring Project, CA, 2015-2017 (cont.)**

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
Frequency of Current Cigars, Cigarillos, or Little Filtered Cigars Smoking					
Rarely	1.4%* (0.0-3.2)	1.2%* (0.0-2.5)	4.0%* (1.5-6.5)	18	2.2% (1.1-3.4)
Some days	0.8%* (0.0-2.3)	0.4%* (0.0-1.3)	0.7%* (0.0-1.7)	<5 obs.	0.6%* (0.0-1.3)
Daily	2.1%* (0.0-4.5)	2.5%* (0.5-4.6)	1.4%* (0.0-2.8)	13	2.0% (0.9-3.1)
Never	95.7% (92.4-99.0)	95.8% (93.3-98.4)	93.9% (90.9-96.9)	588	95.1% (93.4-96.8)
Electronic Cigarette Smoking Status					
Used electronic cigarettes in the past 30 days	3.3%* (0.0-6.7)	7.6% (3.1-12.1)	5.2%* (1.6-8.9)	28	5.4% (3.2-7.6)
Used electronic cigarettes, but not in the past 30 days	19.6% (13.0-26.1)	26.2% (19.6-32.7)	21.5% (15.0-28.0)	143	22.4% (18.6-26.2)
Never used electronic cigarettes	77.1% (70.0-84.2)	66.2% (59.0-73.4)	73.3% (66.3-80.2)	453	72.2% (68.1-76.3)
TOTAL	---	---	---	626	---

Abbreviation: CI, confidence interval. Note: Estimates with a coefficient of variation ≥ 0.30 , a denominator sample size < 30 , an absolute CI width ≥ 0.30 , or an absolute CI width between 0.05 and 0.30 and a relative CI width $> 130\%$ are marked with an asterisk and should be interpreted with caution. ^a Percentages are weighted percentages. ^b CIs incorporate weighted percentages. ^c Numbers are unweighted.

Appendix Table 5.3. Alcohol Use, by Cycle Year - Medical Monitoring Project, CA, 2015-2017

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
Any Alcohol Use^d					
Yes	67.2% (58.8-75.5)	73.6% (67.0-80.2)	62.5% (55.1-69.9)	423	67.6% (63.3-71.9)
No	32.8% (24.5-41.2)	26.4% (19.8-33.0)	37.5% (30.1-44.9)	201	32.4% (28.1-36.7)


Appendix Table 5.3. Alcohol Use, by Cycle Year - Medical Monitoring Project, CA, 2015-2017 (cont.)

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
Frequency of Alcohol Use					
Daily	10.0% (4.1-15.9)	7.3% (3.9-10.7)	8.8% (4.3-13.3)	55	8.7% (6.0-11.4)
Weekly	16.7% (10.1-23.3)	33.3% (26.0-40.7)	17.9% (12.0-23.9)	136	22.6% (18.7-26.4)
Monthly	14.5% (8.3-20.7)	14.1% (8.9-19.4)	16.8% (11.3-22.3)	96	15.2% (11.9-18.4)
Less than monthly	26.0% (17.9-34.0)	18.8% (13.4-24.2)	18.9% (13.3-24.6)	136	21.1% (17.4-24.9)
Never	32.8% (24.5-41.2)	26.4% (19.8-33.0)	37.5% (30.1-44.9)	201	32.4% (28.1-36.7)
Binge Drinking, Past 30 Days^e					
Yes	16.6% (9.9-23.4)	16.2% (10.6-21.8)	11.6% (6.5-16.6)	89	14.7% (11.4-18.0)
No	83.4% (76.6-90.1)	83.8% (78.2-89.4)	88.4% (83.4-93.5)	534	85.3% (82.0-88.6)
TOTAL	---	---	---	626	---

Abbreviation: CI, confidence interval. ^a Percentages are weighted percentages. ^b CIs incorporate weighted percentages. ^c Numbers are unweighted. ^d Persons who drank at least 1 alcoholic beverage during the 12 months before the interview. Alcoholic beverage was defined as a 12-ounce beer, 5-ounce glass of wine, or 1.5-ounce shot of liquor. ^e Persons who drank ≥ 5 alcoholic beverages in a single sitting (≥ 4 for women) during the 30 days before the interview.

Appendix Table 5.4. Non-Injection Drug Use, by Cycle Year - Medical Monitoring Project, CA, 2015-2017

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
Use of Any Non-Injection Drugs^d					
Yes	33.8% (25.0-42.6)	29.8% (23.0-36.6)	37.6% (30.2-45.0)	205	33.8% (29.4-38.2)
No	66.2% (57.4-75.0)	70.2% (63.4-77.0)	62.4% (55.0-69.8)	416	66.2% (61.8-70.6)

**Appendix Table 5.4. Non-Injection Drug Use, by Cycle Year - Medical Monitoring Project, CA, 2015-2017 (cont.)**

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
Non-Injection Drugs Used^d:					
Marijuana					
Yes	30.1% (21.5-38.7)	25.2% (18.8-31.5)	34.7% (27.4-42.0)	181	30.1% (25.8-34.4)
No	69.9% (61.3-78.5)	74.8% (68.5-81.2)	65.3% (58.0-72.6)	440	69.9% (65.6-74.2)
Crack					
Yes	1.4%* (0.0-3.2)	1.0%* (0.0-2.2)	1.4%* (0.0-2.8)	11	1.2%* (0.4-2.1)
No	98.6% (96.8-100.0)	99.0% (97.8-100.0)	98.6% (97.2-100.0)	610	98.8% (97.9-99.6)
Cocaine that is smoked or snorted					
Yes	7.2%* (1.4-13.0)	4.1%* (1.0-7.2)	6.8% (2.8-10.7)	34	6.1% (3.5-8.6)
No	92.8% (87.0-98.6)	95.9% (92.8-99.0)	93.2% (89.3-97.2)	587	93.9% (91.4-96.5)
Methamphetamine (e.g., crystal meth, tina, crank, ice)					
Yes	14.3% (7.1-21.4)	12.8% (7.8-17.8)	10.7% (5.8-15.6)	72	12.6% (9.3-15.9)
No	85.7% (78.6-92.9)	87.2% (82.2-92.2)	89.3% (84.4-94.2)	549	87.4% (84.1-90.7)
Amphetamine (e.g., speed, bennies, uppers)					
Yes	6.4%* (1.6-11.3)	2.0%* (0.2-3.7)	2.1%* (0.0-4.3)	19	3.5% (1.6-5.3)
No	93.6% (88.7-98.4)	98.0% (96.3-99.8)	97.9% (95.7-100.0)	602	96.5% (94.7-98.4)
Club drugs (e.g., Ecstasy or X, ketamine or Special K, GHB or Liquid Ecstasy)					
Yes	6.5%* (2.2-10.7)	7.0%* (2.8-11.2)	2.9%* (0.8-5.0)	36	5.4% (3.3-7.5)
No	93.5% (89.3-97.8)	93.0% (88.8-97.2)	97.1% (95.0-99.2)	585	94.6% (92.5-96.7)


Appendix Table 5.4. Non-Injection Drug Use, by Cycle Year - Medical Monitoring Project, CA, 2015-2017 (cont.)

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
<i>Amyl nitrite (poppers)</i>					
Yes	9.5% (4.0-15.0)	11.3% (6.5-16.1)	9.2% (5.0-13.4)	63	10.0% (7.2-12.8)
No	90.5% (85.0-96.0)	88.7% (83.9-93.5)	90.8% (86.6-95.0)	558	90.0% (87.2-92.8)
<i>Prescription opioids (e.g., oxycodone, hydrocodone, Vicodin, Percocet)^e</i>					
Yes	5.0%* (1.5-8.5)	2.8%* (0.6-4.9)	1.8%* (0.2-3.3)	21	3.1% (1.7-4.6)
No	95.0% (91.5-98.5)	97.2% (95.1-99.4)	98.2% (96.7-99.8)	600	96.9% (95.4-98.3)
<i>Prescription tranquilizers (e.g., Valium, Ativan, Xanax, downers, nerve pills)^e</i>					
Yes	0.5%* (0.0-1.4)	0.9%* (0.0-2.1)	3.0%* (0.8-5.2)	11	1.5%* (0.6-2.4)
No	99.5% (98.6-100.0)	99.1% (97.9-100.0)	97.0% (94.8-99.2)	609	98.5% (97.6-99.4)
TOTAL	---	---	---	626	---

Abbreviations: CI, confidence interval; GHB, gamma hydroxybutyrate. Note: Persons could report taking more than 1 noninjection drug. Estimates with a coefficient of variation ≥ 0.30 , a denominator sample size < 30 , an absolute CI width ≥ 0.30 , or an absolute CI width between 0.05 and 0.30 and a relative CI width $> 130\%$ are marked with an asterisk and should be interpreted with caution. ^a Percentages are weighted percentages. ^b CIs incorporate weighted percentages. ^c Numbers are unweighted. ^d Includes all drugs that were not injected (i.e., administered by any route other than injection), including legal drugs that were not used for medical purposes. ^e Not prescribed, or prescribed but taken more than directed.

Appendix Table 5.5. Injection Drug Use, by Cycle Year - Medical Monitoring Project, CA, 2015-2017

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
<i>Use of Any Injection Drugs</i>					
Yes	3.8%* (0.2-7.3)	4.3% (1.8-6.9)	2.9%* (0.7-5.1)	26	3.6% (2.1-5.2)
No	96.2% (92.7-99.8)	95.7% (93.1-98.2)	97.1% (94.9-99.3)	596	96.4% (94.8-97.9)

**Appendix Table 5.5. Injection Drug Use, by Cycle Year - Medical Monitoring Project, CA, 2015-2017 (cont.)**

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
Injection Drugs Used:					
Cocaine					
Yes	0.0%	0.0%	0.4%* (0.0-1.3)	<5 obs.	0.2%* (0.0-0.5)
No	100.0%	100.0%	99.6% (98.7-100.0)	620	99.8% (99.5-100.0)
Heroin					
Yes	1.4%* (0.0-4.2)	0.6%* (0.0-1.4)	0.9%* (0.0-2.1)	6	1.0%* (0.0-2.0)
No	98.6% (95.8-100.0)	99.4% (98.6-100.0)	99.1% (97.9-100.0)	615	99.0% (98.0-100.0)
Heroin and cocaine (speedball)					
Yes	0.0%	0.1%* (0.0-0.3)	0.4%* (0.0-1.3)	<5 obs.	0.2%* (0.0-0.5)
No	100.0%	99.9% (99.7-100.0)	99.6% (98.7-100.0)	619	99.8% (99.5-100.0)
Methamphetamine (e.g., crystal meth, tina, crank, ice)					
Yes	3.4%* (0.0-6.9)	3.9%* (1.5-6.3)	2.5%* (0.5-4.4)	23	3.2% (1.7-4.8)
No	96.6% (93.1-100.0)	96.1% (93.7-98.5)	97.5% (95.6-99.5)	598	96.8% (95.2-98.3)
Amphetamine (e.g., speed, bennies, uppers)					
Yes	0.3%* (0.0-1.0)	0.9%* (0.0-2.0)	1.6%* (0.0-3.2)	8	1.0%* (0.3-1.7)
No	99.7% (99.0-100.0)	99.1% (98.0-100.0)	98.4% (96.8-100.0)	613	99.0% (98.3-99.7)


Appendix Table 5.5. Injection Drug Use, by Cycle Year - Medical Monitoring Project, CA, 2015-2017 (cont.)

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
Prescription opioids (e.g., OxyContin, oxycodone, hydrocodone)					
Yes	1.4%* (0.0-4.2)	0.5%* (0.0-1.5)	0.0%	<5 obs.	0.6%* (0.0-1.6)
No	98.6% (95.8-100.0)	99.5% (98.5-100.0)	100.0%	619	99.4% (98.4-100.0)
TOTAL	---	---	---	626	---

Abbreviation: CI, confidence interval. Note: Persons could report taking more than 1 injection drug. Estimates with a coefficient of variation ≥ 0.30 , a denominator sample size < 30 , an absolute CI width ≥ 0.30 , or an absolute CI width between 0.05 and 0.30 and a relative CI width $> 130\%$ are marked with an asterisk and should be interpreted with caution. ^a Percentages are weighted percentages. ^b CIs incorporate weighted percentages. ^c Numbers are unweighted.

Appendix Table 6.1a. Sexual Behavior Among Cisgender Men, by Cycle Year - Medical Monitoring Project, CA, 2015-2017

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
Engaged in Anal Sex With Men:					
Receptive					
Yes	44.0% (33.9-54.1)	42.4% (34.3-50.4)	48.7% (40.2-57.2)	62	44.0% (33.9-54.1)
No	56.0% (45.9-66.1)	57.6% (49.6-65.6)	51.3% (42.8-59.8)	83	56.0% (45.9-66.1)
Insertive					
Yes	41.1% (31.1-51.1)	42.8% (34.8-50.9)	44.4% (35.9-52.8)	58	41.1% (31.1-51.1)
No	58.9% (48.9-68.9)	57.2% (49.1-65.2)	55.6% (47.2-64.1)	87	58.9% (48.9-68.9)
Engaged in Anal Sex With Women					
Yes	0.2%* (0.0-0.5)	1.7%* (0.0-3.5)	3.1%* (0.6-5.6)	<5 obs.	0.2%* (0.0-0.5)
No	99.8% (99.5-100.0)	98.3% (96.5-100.0)	96.9% (94.4-99.4)	146	99.8% (99.5-100.0)

**Appendix Table 6.1a. Sexual Behavior Among Cisgender Men, by Cycle Year - Medical Monitoring Project, CA, 2015-2017 (cont.)**

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
Engaged in Vaginal Sex					
Yes	15.0% (8.0-22.1)	6.8% (3.3-10.4)	9.9% (5.5-14.2)	20	15.0% (8.0-22.1)
No	85.0% (77.9-92.0)	93.2% (89.6-96.7)	90.1% (85.8-94.5)	125	85.0% (77.9-92.0)
Engaged in Vaginal or Anal Sex					
Yes	65.2% (56.0-74.3)	58.9% (51.0-66.8)	64.3% (56.4-72.2)	91	65.2% (56.0-74.3)
No	34.8% (25.7-44.0)	41.1% (33.2-49.0)	35.7% (27.8-43.6)	54	34.8% (25.7-44.0)
TOTAL	---	---	---	147	---

Abbreviations: CI, confidence interval. Note: Estimates with a coefficient of variation ≥ 0.30 , a denominator sample size < 30 , an absolute CI width ≥ 0.30 , or an absolute CI width between 0.05 and 0.30 and a relative CI width $> 130\%$ are marked with an asterisk and should be interpreted with caution. ^a Percentages are weighted percentages. ^b CIs incorporate weighted percentages. ^c Numbers are unweighted.

Appendix Table 6.1b. Sexual Behavior Among Cisgender Women, by Cycle Year - Medical Monitoring Project, CA, 2015-2017

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
Engaged in Anal Sex With Men					
Yes	4.9%* (0.0-14.2)	7.3%* (0.0-19.7)	9.3%* (0.3-18.2)	<5 obs.	4.9%* (0.0-14.2)
No	95.1%* (85.8-100.0)	92.7%* (82.1-100.0)	90.7%* (81.8-99.7)	28	95.1%* (85.8-100.0)
Engaged in Vaginal Sex					
Yes	55.9%* (35.8-76.1)	57.3%* (36.5-78.1)	45.7%* (28.6-62.8)	14	55.9%* (35.8-76.1)
No	44.1%* (23.9-64.2)	42.7%* (21.9-63.5)	54.3%* (37.2-71.4)	15	44.1%* (23.9-64.2)



Appendix Table 6.1b. Sexual Behavior Among Cisgender Women, by Cycle Year - Medical Monitoring Project, CA, 2015-2017 (cont.)

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
Engaged in Vaginal or Anal Sex					
Yes	55.9%* (35.8-76.1)	57.3%* (36.5-78.1)	45.7%* (28.6-62.8)	14	55.9%* (35.8-76.1)
No	44.1%* (23.9-64.2)	42.7%* (21.9-63.5)	54.3%* (37.2-71.4)	15	44.1%* (23.9-64.2)
TOTAL	---	---	---	29	---

Abbreviations: CI, confidence interval. Note: Estimates with a coefficient of variation ≥ 0.30 , a denominator sample size < 30 , an absolute CI width ≥ 0.30 , or an absolute CI width between 0.05 and 0.30 and a relative CI width $> 130\%$ are marked with an asterisk and should be interpreted with caution. ^a Percentages are weighted percentages. ^b CIs incorporate weighted percentages. ^c Numbers are unweighted.

Appendix Table 6.3a. Sexual Behavior During the 12 Months Before the Interview Among Men Who Had Sex With Men (MSM), by Cycle Year - Medical Monitoring Project, CA, 2015-2017

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
Engaged in Any High-Risk Sex^d					
Yes	5.6%* (0.3-10.9)	11.0%* (4.1-17.8)	8.0%* (2.0-13.9)	29	8.3% (4.8-11.9)
No	94.4% (89.1-99.7)	89.0% (82.2-95.9)	92.0% (86.1-98.0)	384	91.7% (88.1-95.2)
Engaged in Any High-Risk Sex (among sexually active persons)^d					
Yes	8.0%* (0.5-15.6)	17.0%* (6.9-27.2)	11.4%* (3.0-19.7)	187	68.1% (61.3-74.9)
No	92.0% (84.4-99.5)	83.0% (72.8-93.1)	88.6% (80.3-97.0)	86	31.9% (25.1-38.7)
Percentages of Sexually Active Persons Who Used a Prevention Strategy With at Least 1 Partner: Sex while sustainably virally suppressed^e					
Yes	67.1% (53.4-80.9)	65.4% (54.4-76.4)	71.3% (60.3-82.2)	187	68.1% (61.3-74.9)
No	32.9% (19.1-46.6)	34.6% (23.6-45.6)	28.7% (17.8-39.7)	86	31.9% (25.1-38.7)

Appendix Table 6.3a. Sexual Behavior During the 12 Months Before the Interview Among Men Who Had Sex With Men (MSM), by Cycle Year - Medical Monitoring Project, CA, 2015-2017 (cont.)

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
<i>Condom-protected sex^f</i>					
Yes	49.1% (34.3-64.0)	62.0% (50.6-73.3)	58.5% (46.6-70.3)	162	56.7% (49.4-64.1)
No	50.9% (36.0-65.7)	38.0% (26.7-49.4)	41.5% (29.7-53.4)	110	43.3% (35.9-50.6)
<i>Condomless sex with a partner on PrEP^g</i>					
Yes	11.3%* (2.1-20.5)	13.7% (6.2-21.2)	14.6% (6.5-22.8)	40	13.3% (8.5-18.1)
No	88.7% (79.5-97.9)	86.3% (78.8-93.8)	85.4% (77.2-93.5)	233	86.7% (81.9-91.5)
<i>Sex with an HIV positive partner^h</i>					
Yes	69.5% (56.8-82.3)	67.9% (57.6-78.2)	44.7% (33.2-56.3)	166	59.9% (52.9-66.9)
No	30.5% (17.7-43.2)	32.1% (21.8-42.4)	55.3% (43.7-66.8)	107	40.1% (33.1-47.1)
TOTAL	---	---	---	414	---

Abbreviations: CI, confidence interval; PrEP, pre-exposure prophylaxis. Note: Persons who reported no anal, vaginal or oral sex in the 12 months before the interview were categorized according to self-reported sexual orientation. This table does not include information on women who had sex with women only, women who had sex with transgender people only, or men who had sex with transgender people only. Estimates with a coefficient of variation ≥ 0.30 , a denominator sample size < 30 , an absolute CI width ≥ 0.30 , or an absolute CI width between 0.05 and 0.30 and a relative CI width $> 130\%$ are marked with an asterisk and should be interpreted with caution. ^a Percentages are weighted percentages. ^b CIs incorporate weighted percentages. ^c Numbers are unweighted. ^d Vaginal or anal sex with at least 1 HIV-negative or unknown status partner while not sustainably virally suppressed, a condom was not used, and the partner was not on PrEP. PrEP use was only measured among the five most recent partners. ^e HIV viral load < 200 copies/mL documented in the medical record at every measure in the past 12 months before the interview. ^f Condoms were consistently used with at least 1 vaginal or anal sex partner. ^g At least 1 HIV-negative condomless-sex partner was on PrEP. PrEP use was only measured among the five most recent partners and was reported by the HIV-positive partner. ^h Sex with at least 1 HIV-positive partner.



Appendix Table 6.3b. Sexual Behavior During the 12 Months Before the Interview Among Men Who Had Sex Only With Women (MSW), by Cycle Year - Medical Monitoring Project, CA, 2015-2017

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
<i>Engaged in Any High-Risk Sex^d</i>					
Yes	3.1%* (0.0-9.2)	0.8%* (0.0-2.5)	8.9%* (0.0-18.7)	5	4.3%* (0.2-8.4)
No	91.6% (90.8-100.0)	99.2% (97.5-100.0)	91.1% (81.3-100.0)	88	95.7% (91.6-99.8)
<i>Engaged in Any High-Risk Sex (among sexually active persons)^d</i>					
Yes	5.8%* (0.0-17.1)	2.2%* (0.0-6.7)	25.0%* (0.1-50.0)	5	9.7%* (0.7-18.7)
No	94.2% (82.9-100.0)	97.8% (93.3-100.0)	75.0%* (50.0-99.9)	39	90.3% (81.3-99.3)
<i>Percentages of Sexually Active Persons Who Used a Prevention Strategy With at Least 1 Partner:</i>					
<i>Sex while sustainably virally suppressed^e</i>					
Yes	47.1%* (21.0-73.2)	49.3%* (19.4-79.2)	52.0%* (24.1-79.9)	22	48.8%* (31.9-65.7)
No	52.9%* (26.8-79.0)	50.7%* (20.8-80.6)	48.0% (20.1-75.9)	23	51.2%* (34.3-68.1)
<i>Condom-protected sex^f</i>					
Yes	69.3%* (41.3-97.2)	75.6%* (50.7-100.0)	72.9%* (47.6-98.1)	33	71.5%* (54.1-88.9)
No	30.7%* (2.8-58.7)	24.4%* (0.0-49.3)	27.1%* (1.9-52.4)	11	28.5%* (11.1-45.9)
<i>Condomless sex with a partner on PrEP^g</i>					
Yes	0.0%	11.7%* (0.0-29.9)	0.0%	<5 obs.	2.4%* (0.0-6.4)
No	100.0%	88.3% (70.1-100.0)	100.0%	43	97.6% (93.6-100.0)

Appendix Table 6.3b. Sexual Behavior During the 12 Months Before the Interview Among Men Who Had Sex Only With Women (MSW), by Cycle Year - Medical Monitoring Project, CA, 2015-2017 (cont.)

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
<i>Sex with an HIV positive partner^h</i>					
Yes	35.9%* (8.3-63.6)	23.4%* (0.0-49.0)	15.9%* (0.0-36.3)	9	28.2%* (10.9-45.6)
No	64.1%* (36.4-91.7)	76.6%* (51.0-100.0)	84.1%* (63.7-100.0)	36	71.8%* (54.4-89.1)
TOTAL	---	---	---	95	---

Abbreviations: CI, confidence interval; PrEP, pre-exposure prophylaxis. Note: Persons who reported no anal, vaginal or oral sex in the 12 months before the interview were categorized according to self-reported sexual orientation. This table does not include information on women who had sex with women only, women who had sex with transgender people only, or men who had sex with transgender people only. Estimates with a coefficient of variation ≥ 0.30 , a denominator sample size < 30 , an absolute CI width ≥ 0.30 , or an absolute CI width between 0.05 and 0.30 and a relative CI width $> 130\%$ are marked with an asterisk and should be interpreted with caution. ^a Percentages are weighted percentages. ^b CIs incorporate weighted percentages. ^c Numbers are unweighted. ^d Vaginal or anal sex with at least 1 HIV-negative or unknown status partner while not sustainably virally suppressed, a condom was not used, and the partner was not on PrEP. PrEP use was only measured among the five most recent partners. ^e HIV viral load < 200 copies/mL documented in the medical record at every measure in the past 12 months before the interview. ^f Condoms were consistently used with at least 1 vaginal or anal sex partner. ^g At least 1 HIV-negative condomless-sex partner was on PrEP. PrEP use was only measured among the five most recent partners and was reported by the HIV-positive partner. ^h Sex with at least 1 HIV-positive partner.

Appendix Table 6.3c. Sexual Behavior During the 12 Months Before the Interview Among Women Who Had Sex With Men (WSM), by Cycle Year - Medical Monitoring Project, CA, 2015-2017

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
<i>Engaged in Any High-Risk Sex^d</i>					
Yes	0.6%* (0.0-1.7)	0.0%	2.4%* (0.0-7.2)	<5 obs.	1.0%* (0.0-2.7)
No	99.4% (98.3-100.0)	100.0%	97.6% (92.8-100.0)	92	99.0% (97.3-100.0)
<i>Engaged in Any High-Risk Sex (among sexually active persons)^d</i>					
Yes	1.0%* (0.0-3.0)	0.0%	5.2%* (0.0-15.2)	<5 obs.	1.9%* (0.0-5.0)
No	99.0% (97.0-100.0)	100.0%	94.8% (84.8-100.0)	45	98.1% (95.0-100.0)



Appendix Table 6.3c. Sexual Behavior During the 12 Months Before the Interview Among Women Who Had Sex With Men (WSM), by Cycle Year - Medical Monitoring Project, CA, 2015-2017 (cont.)

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
Percentages of Sexually Active Persons Who Used a Prevention Strategy With at Least 1 Partner:					
<i>Sex while sustainably virally suppressed^e</i>					
Yes	63.7%* (33.0-94.3)	96.0% (88.2-100.0)	84.6%* (68.3-100.0)	39	81.2% (67.4-95.0)
No	36.3%* (5.7-67.0)	4.0%* (0.0-11.8)	15.4%* (0.0-31.1)	8	18.8%* (5.0-32.6)
<i>Condom-protected sex^f</i>					
Yes	54.9%* (25.3-84.6)	34.1%* (6.7-61.4)	41.7%* (18.9-64.5)	21	43.7%* (27.8-59.7)
No	45.1%* (15.4-74.7)	65.9%* (38.6-93.3)	58.3%* (35.5-81.1)	26	56.3%* (40.3-72.2)
<i>Condomless sex with a partner on PrEP^g</i>					
Yes	0.0%	0.0%	0.0%	---	0.0%
No	100.0%	100.0%	100.0%	---	100.0%
<i>Sex with an HIV positive partner^h</i>					
Yes	62.6%* (33.6-91.6)	16.4%* (0.1-32.8)	28.1%* (6.1-50.2)	17	36.2%* (20.9-51.5)
No	37.4%* (8.4-66.4)	83.6%* (67.2-99.9)	71.9%* (49.8-93.9)	30	63.8%* (48.5-79.1)
TOTAL	---	---	---	95	---

Abbreviations: CI, confidence interval; PrEP, pre-exposure prophylaxis. Note: Persons who reported no anal, vaginal or oral sex in the 12 months before the interview were categorized according to self-reported sexual orientation. This table does not include information on women who had sex with women only, women who had sex with transgender people only, or men who had sex with transgender people only. Estimates with a coefficient of variation ≥ 0.30 , a denominator sample size < 30 , an absolute CI width ≥ 0.30 , or an absolute CI width between 0.05 and 0.30 and a relative CI width $> 130\%$ are marked with an asterisk and should be interpreted with caution. ^a Percentages are weighted percentages. ^b CIs incorporate weighted percentages. ^c Numbers are unweighted. ^d Vaginal or anal sex with at least 1 HIV-negative or unknown status partner while not sustainably virally suppressed, a condom was not used, and the partner was not on PrEP. PrEP use was only measured among the five most recent partners. ^e HIV viral load < 200 copies/mL documented in the medical record at every measure in the past 12 months before the interview. ^f Condoms were consistently used with at least 1 vaginal or anal sex partner. ^g At least 1 HIV-negative condomless-sex partner was on PrEP. PrEP use was only measured among the five most recent partners and was reported by the HIV-positive partner. ^h Sex with at least 1 HIV-positive partner.

**Appendix Table 7.1. Intimate Partner Violence and Sexual Violence, by Cycle Year - Medical Monitoring Project, CA, 2015-2017**

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
<i>Was ever slapped, punched, shoved, kicked, choked or otherwise physically hurt by a romantic or sexual partner</i>					
Yes	28.0% (19.7-36.3)	24.2% (17.8-30.7)	30.1% (22.8-37.3)	172	27.5% (23.3-31.7)
No	72.0% (63.7-80.3)	75.8% (69.3-82.2)	69.9% (62.7-77.2)	445	72.5% (68.3-76.7)
<i>Was slapped, punched, shoved, kicked, choked or otherwise physically hurt by a romantic or sexual partner, past 12 months</i>					
Yes	5.0%* (0.3-9.7)	3.9%* (0.8-7.0)	5.3%* (1.6-9.1)	24	4.8% (2.5-7.0)
No	95.0% (90.3-99.7)	96.1% (93.0-99.2)	94.7% (90.9-98.4)	593	95.2% (93.0-97.5)
<i>Was ever threatened with harm or physically forced to have unwanted vaginal, anal, or oral sex</i>					
Yes	15.8% (10.2-21.3)	16.5% (11.0-22.1)	19.5% (13.1-25.9)	119	17.3% (13.9-20.7)
No	84.2% (78.7-89.8)	83.5% (77.9-89.0)	80.5% (74.1-86.9)	498	82.7% (79.3-86.1)
<i>Was threatened with harm or physically forced to have unwanted vaginal, anal, or oral sex, past 12 months</i>					
Yes	1.2%* (0.0-2.9)	2.8%* (0.0-5.6)	1.7%* (0.1-3.2)	12	1.9%* (0.7-3.1)
No	98.8% (97.1-100.0)	97.2% (94.4-100.0)	98.3% (96.8-99.9)	605	98.1% (96.9-99.3)
TOTAL	---	---	---	626	---

Abbreviation: CI, confidence interval. Note: Estimates with a coefficient of variation ≥ 0.30 , a denominator sample size < 30 , an absolute CI width ≥ 0.30 , or an absolute CI width between 0.05 and 0.30 and a relative CI width $> 130\%$ are marked with an asterisk and should be interpreted with caution. ^a Percentages are weighted percentages. ^b CIs incorporate weighted percentages. ^c Numbers are unweighted.


Appendix Table 8.1a. Met and Unmet Need for Ancillary Services, by Cycle Year - Medical Monitoring Project, CA, 2015-2017

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
<i>Dental Care</i>					
Needed, but did not receive service	24.0% (16.5-31.4)	20.8% (14.6-27.1)	21.7% (15.6-27.8)	143	22.1% (18.3-25.9)
Received service	59.3% (50.6-68.0)	65.2% (58.0-72.4)	63.8% (56.5-71.0)	390	62.8% (58.3-67.3)
Did not need, did not receive service	16.8% (10.3-23.2)	14.0% (8.7-19.3)	14.6% (9.0-20.1)	91	15.1% (11.7-18.4)
<i>SNAP or WIC</i>					
Needed, but did not receive service	14.9% (8.3-21.4)	11.4% (6.8-16.0)	9.1% (4.7-13.4)	76	11.7% (8.7-14.7)
Received service	15.8% (9.4-22.3)	25.1% (18.5-31.8)	17.2% (11.7-22.7)	120	19.4% (15.8-23.0)
Did not need, did not receive service	69.3% (61.0-77.6)	63.5% (56.2-70.7)	73.7% (67.2-80.3)	428	69.0% (64.7-73.2)
<i>Transportation Assistance</i>					
Needed, but did not receive service	15.3% (9.0-21.6)	6.4% (3.2-9.6)	7.8%* (3.1-12.4)	60	9.7% (7.0-12.5)
Received service	15.6% (9.3-21.9)	16.5% (11.1-21.9)	18.0% (12.6-23.5)	111	16.7% (13.5-20.0)
Did not need, did not receive service	69.1% (61.0-77.2)	77.1% (71.1-83.1)	74.2% (67.6-80.8)	453	73.5% (69.5-77.5)
<i>Mental Health Services</i>					
Needed, but did not receive service	12.8% (7.0-18.5)	9.0% (4.1-13.9)	6.6% (3.5-9.7)	61	9.4% (6.7-12.1)
Received service	32.9% (24.4-41.3)	29.3% (22.8-35.8)	33.9% (26.8-41.0)	205	32.1% (27.8-36.3)
Did not need, did not receive service	54.4% (45.4-63.3)	61.6% (54.4-68.9)	59.5% (52.2-66.9)	357	58.6% (54.0-63.1)

**Appendix Table 8.1a. Met and Unmet Need for Ancillary Services, by Cycle Year - Medical Monitoring Project, CA, 2015-2017 (cont.)**

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
Shelter or Housing Services					
Needed, but did not receive service	9.7% (4.7-14.6)	11.9% (6.8-17.1)	6.6% (3.6-9.6)	64	9.3% (6.8-11.9)
Received service	13.3% (8.0-18.7)	9.5% (5.3-13.7)	13.8% (9.4-18.3)	85	12.2% (9.6-14.9)
Did not need, did not receive service	77.0% (70.1-84.0)	78.6% (72.4-84.8)	79.6% (74.4-84.9)	475	78.4% (74.9-82.0)
HIV Peer Group Support					
Needed, but did not receive service	10.5% (5.4-15.6)	9.9% (5.2-14.5)	7.7% (4.3-11.1)	62	9.3% (6.8-11.9)
Received service	7.4% (3.5-11.3)	8.5% (4.5-12.5)	14.0% (8.9-19.1)	72	10.1% (7.5-12.6)
Did not need, did not receive service	82.1% (75.8-88.3)	81.7% (75.9-87.5)	78.3% (72.4-84.1)	489	80.6% (77.2-84.1)
Meal or Food Services^d					
Needed, but did not receive service	8.8% (4.1-13.6)	9.0% (4.5-13.4)	6.6%* (2.6-10.7)	50	8.1% (5.6-10.6)
Received service	24.8% (17.3-32.4)	15.0% (9.7-20.3)	21.0% (15.1-26.9)	126	20.3% (16.6-23.9)
Did not need, did not receive service	66.4% (58.1-74.6)	76.1% (69.6-82.5)	72.4% (65.7-79.1)	447	71.7% (67.5-75.8)
HIV Case Management Services					
Needed, but did not receive service	6.9%* (2.8-11.1)	9.7% (5.1-14.2)	6.6% (3.0-10.2)	51	7.7% (5.3-10.1)
Received service	48.1% (39.1-57.0)	43.5% (36.2-50.8)	50.1% (42.5-57.7)	300	47.3% (42.7-51.9)
Did not need, did not receive service	45.0% (36.0-54.0)	46.8% (39.4-54.3)	43.3% (35.8-50.7)	272	45.0% (40.4-49.6)


Appendix Table 8.1a. Met and Unmet Need for Ancillary Services, by Cycle Year - Medical Monitoring Project, CA, 2015-2017 (cont.)

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
Patient Navigation Services					
Needed, but did not receive service	5.2%* (2.1-8.3)	4.9% (2.1-7.6)	5.4% (2.5-8.4)	40	5.2% (3.5-6.9)
Received service	8.0% (3.5-12.4)	9.6% (5.6-13.6)	11.4% (6.7-16.0)	70	9.7% (7.2-12.2)
Did not need, did not receive service	86.8% (81.5-92.1)	85.6% (80.0-90.3)	83.2% (77.8-88.6)	513	85.1% (82.1-88.1)
Medicine Through ADAP					
Needed, but did not receive service	3.1%* (0.8-5.5)	7.4%* (2.8-12.0)	2.6%* (0.0-5.8)	25	4.3% (2.3-6.4)
Received service	52.9% (43.9-61.9)	47.5% (40.1-55.0)	46.2% (38.6-53.7)	316	48.8% (44.1-53.4)
Did not need, did not receive service	44.0% (35.0-53.0)	45.1% (37.7-52.5)	51.3% (43.6-58.9)	273	46.9% (42.2-51.5)
Drug or Alcohol Counseling or Treatment					
Needed, but did not receive service	3.5%* (0.1-7.0)	2.1%* (0.3-4.0)	3.3%* (0.5-6.2)	17	3.0% (1.4-4.6)
Received service	11.3% (5.1-17.4)	6.7% (3.4-10.0)	5.0%* (2.0-8.0)	49	7.6% (5.1-10.1)
Did not need, did not receive service	85.2% (78.4-92.0)	91.2% (87.5-94.9)	91.7% (87.6-95.8)	557	89.4% (86.5-92.3)
Professional HIV Medication Adherence Support Services					
Needed, but did not receive service	0.9%* (0.0-2.2)	1.7%* (0.0-3.4)	1.5%* (0.1-2.8)	11	1.4%* (0.5-2.2)
Received service	29.1% (21.4-36.9)	26.3% (20.1-32.4)	27.8% (21.1-34.6)	186	27.7% (23.8-31.7)
Did not need, did not receive service	70.0% (62.1-77.8)	72.0% (65.7-78.3)	70.7% (63.9-77.6)	426	70.9% (66.9-74.9)

Appendix Table 8.1a. Met and Unmet Need for Ancillary Services, by Cycle Year - Medical Monitoring Project, CA, 2015-2017 (cont.)

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
Domestic Violence Services					
Needed, but did not receive service	2.3%* (0.0-5.7)	1.0%* (0.0-2.3)	0.3%* (0.0-1.0)	6	1.2%* (0.0-2.4)
Received service	0.0%	0.7%* (0.0-1.8)	0.4%* (0.0-1.3)	<5 obs.	0.4%* (0.0-0.9)
Did not need, did not receive service	97.7% (94.3-100.0)	98.3% (96.6-99.9)	99.2% (98.1-100.0)	614	98.4% (97.1-99.7)
Interpreter Services					
Needed, but did not receive service	0.0%	1.2%* (0.0-3.6)	1.5%* (0.0-3.2)	<5 obs.	0.9%* (0.0-1.9)
Received service	6.3%* (2.4-10.2)	2.0%* (0.2-3.7)	6.4% (3.4-9.5)	33	4.9% (3.2-6.7)
Did not need, did not receive service	93.7% (89.8-97.6)	96.8% (93.9-99.7)	92.1% (88.6-95.6)	587	94.2% (92.2-96.1)
TOTAL	---	---	---	626	---

Abbreviations: CI, confidence interval; ADAP, AIDS Drug Assistance Program; SNAP, Supplemental Nutrition Assistance Program; WIC, Special Supplemental Nutrition Program for Women, Infants, and Children. Note: Persons could report receiving or needing more than one service. Estimates with a coefficient of variation ≥ 0.30 , a denominator sample size < 30 , an absolute CI width ≥ 0.30 , or an absolute CI width between 0.05 and 0.30 and a relative CI width $> 130\%$ are marked with an asterisk and should be interpreted with caution.^a Percentages are weighted percentages.^b CIs incorporate weighted percentages.^c Numbers are unweighted.^d Includes services such as soup kitchens, food pantries, food banks, church dinners, or food delivery services.



Appendix Table 8.1b. Met and Unmet Need for Ancillary Services Among People Living With Diagnosed HIV With High Stigma Score, by Cycle Year - Medical Monitoring Project, CA, 2015-2017

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
Dental Care					
Needed, but did not receive service	32.5%* (12.9-52.1)	38.8% (23.9-53.7)	27.7% (12.8-42.5)	44	33.4% (24.0-42.8)
Received service	56.5% (36.7-76.2)	51.4% (36.3-66.4)	57.9% (42.6-73.2)	86	55.0% (45.4-64.5)
Did not need, did not receive service	11.1%* (1.3-20.8)	9.8%* (0.0-19.8)	14.4%* (3.4-25.4)	17	11.7% (5.7-17.6)
SNAP or WIC					
Needed, but did not receive service	26.1%* (9.4-42.8)	12.3%* (4.1-20.4)	13.4%* (3.9-22.9)	29	16.7% (10.0-23.3)
Received service	23.7%* (6.4-41.1)	41.6% (26.5-56.6)	29.7% (16.6-42.9)	45	32.6% (23.6-41.5)
Did not need, did not receive service	50.2% (30.5-70.0)	46.2% (31.2-61.2)	56.9% (42.3-71.4)	73	50.8% (41.3-60.3)
Transportation Assistance					
Needed, but did not receive service	45.9% (26.2-65.7)	10.3%* (2.3-18.2)	13.2%* (0.0-26.9)	28	21.6% (13.3-30.0)
Received service	18.8%* (3.1-34.5)	22.0%* (8.9-35.1)	24.8% (11.9-37.7)	31	22.0% (14.0-30.0)
Did not need, did not receive service	35.3% (16.6-54.0)	67.8% (53.7-81.9)	61.9% (46.5-77.3)	88	56.4% (46.9-65.9)
Mental Health Services					
Needed, but did not receive service	18.4%* (5.6-31.3)	8.9%* (0.0-18.3)	9.9%* (1.2-18.6)	20	12.0% (6.1-17.8)
Received service	45.8% (26.1-65.6)	32.3% (18.9-45.8)	59.6% (45.4-73.7)	66	45.0% (35.6-54.4)
Did not need, did not receive service	35.7% (16.2-55.3)	58.8% (44.2-73.5)	30.5% (17.8-43.3)	61	43.0% (33.6-52.4)

Appendix Table 8.1b. Met and Unmet Need for Ancillary Services Among People Living With Diagnosed HIV With High Stigma Score, by Cycle Year - Medical Monitoring Project, CA, 2015-2017 (cont.)

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
Shelter or Housing Services					
Needed, but did not receive service	21.6%* (4.8-38.4)	27.9% (14.2-41.7)	12.3%* (3.7-20.9)	30	21.1% (13.2-28.9)
Received service	14.2%* (2.3-26.2)	15.7%* (4.9-26.6)	21.4% (10.3-32.4)	29	17.1% (10.6-23.6)
Did not need, did not receive service	64.1% (45.5-82.8)	56.4% (41.4-71.3)	66.4% (53.2-79.5)	88	61.8% (52.7-70.9)
HIV Peer Group Support					
Needed, but did not receive service	13.4%* (1.9-24.9)	14.4%* (3.5-25.3)	10.9%* (2.8-18.9)	20	13.0% (7.0-19.0)
Received service	18.8%* (5.2-32.3)	13.2%* (2.6-23.8)	22.5% (10.3-34.7)	26	17.8% (10.9-24.7)
Did not need, did not receive service	67.8% (50.9-84.8)	72.4% (58.6-86.2)	66.7% (53.1-80.3)	101	69.2% (60.8-77.7)
Meal or Food Services^d					
Needed, but did not receive service	22.3%* (6.3-38.3)	14.0%* (3.2-24.8)	15.6%* (4.8-26.5)	25	16.9% (9.8-24.1)
Received service	32.5% (14.5-50.5)	12.9%* (2.7-23.1)	25.5% (13.7-37.3)	34	22.7% (15.0-30.3)
Did not need, did not receive service	45.2% (25.4-65.1)	73.1% (59.5-86.7)	58.9% (44.6-73.2)	88	60.4% (51.2-69.6)
HIV Case Management Services					
Needed, but did not receive service	20.6%* (5.0-36.2)	16.3%* (3.9-28.8)	15.7%* (5.0-26.4)	23	17.4% (9.9-24.8)
Received service	44.9% (25.1-64.6)	43.6% (29.3-57.9)	48.7% (33.7-63.6)	71	45.6% (36.2-55.0)
Did not need, did not receive service	34.6% (15.8-53.3)	40.1% (24.8-55.4)	35.7% (22.0-49.3)	53	37.1% (27.8-46.3)



Appendix Table 8.1b. Met and Unmet Need for Ancillary Services Among People Living With Diagnosed HIV With High Stigma Score, by Cycle Year - Medical Monitoring Project, CA, 2015-2017 (cont.)

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
Patient Navigation Services					
Needed, but did not receive service	4.4%* (0.0-10.4)	5.1%* (0.0-11.1)	18.6%* (7.2-30.1)	14	9.2% (4.4-14.1)
Received service	7.6%* (0.3-14.8)	18.3% (8.2-28.4)	19.5%* (4.7-34.3)	26	15.5% (8.9-22.2)
Did not need, did not receive service	88.1% (78.7-97.5)	76.6% (65.3-88.0)	61.9% (46.4-77.3)	107	75.2% (67.4-83.0)
Medicine Through ADAP					
Needed, but did not receive service	5.3%* (0.0-12.5)	13.9%* (1.5-26.3)	2.0%* (0.0-5.5)	9	7.6%* (2.0-13.1)
Received service	52.5% (32.3-72.7)	44.2% (29.5-59.0)	66.6% (53.2-80.0)	80	53.9% (44.4-63.4)
Did not need, did not receive service	42.2% (22.3-62.2)	41.9% (27.2-56.7)	31.4% (18.2-44.5)	55	38.6% (29.4-47.8)
Drug or Alcohol Counseling or Treatment					
Needed, but did not receive service	4.9%* (0.0-12.1)	3.2%* (0.0-7.6)	4.3%* (0.0-9.6)	7	4.1%* (0.9-7.3)
Received service	14.3%* (0.0-30.1)	9.1%* (1.9-16.2)	6.1%* (0.0-12.4)	14	9.6%* (3.8-15.5)
Did not need, did not receive service	80.8% (64.1-97.4)	87.7% (79.4-96.0)	89.6% (81.5-97.8)	126	86.3% (79.8-92.8)
Professional HIV Medication Adherence Support Services					
Needed, but did not receive service	2.2%* (0.0-6.5)	0.0%	1.9%* (0.0-4.8)	<5 obs.	1.2%* (0.0-2.8)
Received service	39.2% (20.3-58.0)	28.0% (15.9-40.1)	33.6% (18.9-48.4)	53	33.1% (24.4-41.8)
Did not need, did not receive service	58.7% (39.6-77.7)	72.0% (59.9-84.1)	64.5% (49.7-79.3)	90	65.7% (56.9-74.5)

Appendix Table 8.1b. Met and Unmet Need for Ancillary Services Among People Living With Diagnosed HIV With High Stigma Score, by Cycle Year - Medical Monitoring Project, CA, 2015-2017 (cont.)

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
Domestic Violence Services					
Needed, but did not receive service	7.6%* (0.0-21.6)	1.7%* (0.0-5.0)	0.0%	<5 obs.	2.9%* (0.0-7.4)
Received service	0.0%	0.0%	2.1%* (0.0-6.3)	<5 obs.	0.7%* (0.0-2.0)
Did not need, did not receive service	92.4% (78.4-100.0)	98.3% (95.0-100.0)	97.9% (93.8-100.0)	143	96.4% (91.8-100.0)
Interpreter Services					
Needed, but did not receive service	0.0%	4.4%* (0.0-12.9)	3.4%* (0.0-10.0)	<5 obs.	2.8%* (0.0-6.7)
Received service	3.0%* (0.0-8.8)	4.1%* (0.0-8.8)	7.2%* (0.9-13.5)	9	4.8%* (1.6-8.0)
Did not need, did not receive service	97.0% (91.2-100.0)	91.5% (82.1-100.0)	89.4% (80.6-98.2)	136	92.4% (87.5-97.4)
TOTAL	---	---	---	147	---

Abbreviations: CI, confidence interval; ADAP, AIDS Drug Assistance Program; SNAP, Supplemental Nutrition Assistance Program; WIC, Special Supplemental Nutrition Program for Women, Infants, and Children. Note: Persons could report receiving or needing more than one service. Estimates with a coefficient of variation ≥ 0.30 , a denominator sample size < 30 , an absolute CI width ≥ 0.30 , or an absolute CI width between 0.05 and 0.30 and a relative CI width $> 130\%$ are marked with an asterisk and should be interpreted with caution. ^a Stigma scores were measured with a ten-item scale ranging from 0 (no stigma) to 100 (high stigma) that measures four dimensions of HIV stigma: personalized stigma, disclosure concerns, negative self-image, and perceived public attitudes about people living with HIV. People were classified as having experienced high levels of HIV stigma if their score on the HIV stigma scale was in the top quartile for the 2015-2017 combined sample (score of ≥ 57.5). ^a Percentages are weighted percentages. ^b CIs incorporate weighted percentages. ^c Numbers are unweighted. ^d Includes services such as soup kitchens, food pantries, food banks, church dinners, or food delivery services.


Appendix Table 9.1. Prevention Services Use, by Cycle Year - Medical Monitoring Project, CA, 2015-2017

	2015	2016	2017		TOTAL
	% ^a (95% CI) ^b	% ^a (95% CI) ^b	% ^a (95% CI) ^b	# ^c	% ^a (95% CI) ^b
<i>One-on-one HIV/STD risk-reduction conversation with physician, nurse, or other health care worker</i>					
Yes	58.8% (50.2-67.4)	44.4% (37.0-51.8)	48.8% (41.2-56.4)	308	50.6% (46.0-55.2)
No	41.2% (32.6-49.8)	55.6% (48.2-63.0)	51.2% (43.6-58.8)	315	49.4% (44.8-54.0)
<i>One-on-one HIV/STD risk-reduction conversation with outreach worker, counselor, or prevention program worker</i>					
Yes	28.7% (20.6-36.7)	28.9% (22.2-35.6)	23.4% (16.9-30.0)	163	26.9% (22.8-31.0)
No	71.3% (63.3-79.4)	71.1% (64.4-77.8)	76.6% (70.0-83.1)	461	73.1% (69.0-77.2)
<i>Attended an organized HIV/STD risk-reduction session involving a small group of people</i>					
Yes	12.4% (6.5-18.3)	9.1% (4.5-13.6)	9.1% (5.2-13.0)	62	10.1% (7.4-12.9)
No	87.6% (81.7-93.5)	90.9% (86.4-95.5)	90.9% (87.0-94.8)	562	89.9% (87.1-92.6)
<i>Received free condoms</i>					
Yes	53.6% (44.6-62.6)	48.5% (41.0-56.0)	47.3% (39.8-54.9)	306	49.7% (45.1-54.4)
No	46.4% (37.4-55.4)	51.5% (44.0-59.0)	52.7% (45.1-60.2)	318	50.3% (45.6-54.9)
TOTAL	---	---	---	626	---

Abbreviation: CI, confidence interval. Note: Persons could report receiving more than one prevention service. ^a Percentages are weighted percentages. ^b CIs incorporate weighted percentages. ^c Numbers are unweighted.

Appendix Table 10.1. High HIV Stigma^a by Selected Characteristics and Cycle Year - Medical Monitoring Project, CA, 2015-2017

	2015	2016	2017		TOTAL
	% ^b (95% CI) ^c	% ^b (95% CI) ^c	% ^b (95% CI) ^c	# ^d	% ^b (95% CI) ^c
Gender					
Male	22.5% (13.9-31.2)	29.0% (21.2-36.9)	21.8% (15.0-28.6)	118	24.5% (20.0-29.0)
Female	23.0%* (6.9-39.1)	26.8%* (9.7-43.9)	30.5% (14.9-46.1)	28	26.8% (17.4-36.2)
Transgender ^e	0.0%	0.0%	21.7%* (0.0-60.5)	<5 obs.	26.8%* (0.0-60.5)
Sexual Orientation					
Lesbian or gay	20.4% (10.4-30.4)	20.7% (12.5-29.0)	18.7% (10.9-26.5)	70	19.9% (14.9-24.9)
Heterosexual or straight	25.7% (11.7-39.7)	29.4% (16.3-42.6)	34.6% (21.7-47.4)	51	29.5% (21.7-37.4)
Bisexual	40.4%* (3.8-76.9)	53.3% (30.3-76.4)	21.2%* (3.2-39.1)	20	37.6% (23.0-52.1)
Other	0.0%*	57.2%* (18.3-96.2)	27.5%* (0.0-58.1)	6	35.8%* (9.9-61.7)
Race/Ethnicity					
American Indian/Alaska Native	---	21.9%* (0.0-64.6)	31.6%* (0.0-83.7)	<5 obs.	25.6%* (0.0-59.5)
Asian	100.0%*	51.0%* (1.8-100.0)	0.0%*	<5 obs.	27.8%* (0.0-56.2)
Black/African American	20.0%* (2.6-37.4)	51.1% (32.6-69.5)	21.7%* (8.3-35.1)	30	32.8% (21.9-43.6)
Latinx ^f	21.1%* (8.0-34.1)	24.6% (13.0-36.3)	25.9% (16.0-35.8)	53	23.8% (17.1-30.6)
Native Hawaiian/Other Pacific Islander	0.0%*	---	100.0%*	0	0.0%*
White	19.4%* (6.6-32.2)	25.9% (15.1-36.7)	19.1% (8.6-29.5)	44	21.3% (14.8-27.9)
Multiple races	42.1%* (13.9-70.4)	3.5%* (0.0-10.3)	59.4% (28.3-90.6)	15	29.4% (15.0-43.7)



Appendix Table 10.1. High HIV Stigma^a by Selected Characteristics and Cycle Year - Medical Monitoring Project, CA, 2015-2017 (cont.)

	2015	2016	2017		TOTAL
	% ^b (95% CI) ^c	% ^b (95% CI) ^c	% ^b (95% CI) ^c	# ^d	% ^b (95% CI) ^c
Age at Time of Interview (yr)					
18–29	4.2%* (0.0-13.6)	41.0% (17.0-65.0)	5.7%* (0.0-14.6)	11	22.0%* (8.2-35.9)
30–39	44.2% (19.0-69.4)	28.9%* (10.4-47.4)	27.8%* (10.9-44.7)	26	33.5% (21.6-45.4)
40–49	17.7%* (1.3-34.0)	30.1% (15.9-44.3)	30.7% (16.2-45.2)	38	26.3% (17.6-35.0)
≥50	20.4% (11.1-29.8)	25.6% (15.6-35.7)	21.1% (13.1-29.1)	72	22.2% (16.9-27.4)
TOTAL	---	---	---	584	---

Abbreviations: CI, confidence interval. Note: Estimates with a coefficient of variation ≥ 0.30 , a denominator sample size < 30 , an absolute CI width ≥ 0.30 , or an absolute CI width between 0.05 and 0.30 and a relative CI width $> 130\%$ are marked with an asterisk and should be interpreted with caution. ^a Stigma scores were measured with a ten-item scale ranging from 0 (no stigma) to 100 (high stigma) that measures four dimensions of HIV stigma: personalized stigma, disclosure concerns, negative self-image, and perceived public attitudes about people living with HIV. People were classified as having experienced high levels of HIV stigma if their score on the HIV stigma scale was in the top quartile for the 2015-2017 combined sample (score of ≥ 57.5). ^b Percentages are weighted percentages. ^c CIs incorporate weighted percentages. ^d Numbers are unweighted. ^e People were classified as transgender if sex at birth and gender reported by the person were different, or if the person chose "transgender" in response to the question about self-identified gender. ^f Latinx people might be of any race. Persons are classified in only one race/ethnicity category.



**MEDICAL
MONITORING
PROJECT**

California Department of Public Health
Office of AIDS
MS 7700
P.O. Box 997426
Sacramento, CA 95899-74726
www.cdph.ca.gov/Programs/CID/DOA